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Nearly all cellular processes are controlled by a highly complex genetic and epigenetic 
network. Although much of this complexity is still unknown to us, we have nonetheless 
begun exploring, perturbing, and creating genetic circuits in cells. To truly understand 
and control a cell, we have to build it from scratch, but as of today, this remains a remote 
possibility. As oppose to the bottom-up approach, a top-down approach is what I have 
undertaken in my dissertation. Regardless of the route, the ultimate aim is the same – to 
be able to program cells like we do to robots today. 
 
Two general approaches will be discussed in this dissertation. In the first half, we will 
look into reprogramming via the introduction of external network components such as an 
artificial transcription factor (gene switch) or a pathway. In one example, we report the 
development of a gene switch that is able to regulate the endogenous VEGF-A expression 
in mammalian cell. The gene switch is specifically and reversibly controlled by 4,4’-
dyhydroxybenzil (DHB), a small molecule, non-steroid synthetic ligand, which acts 
orthogonally in a mammalian system. After optimization of the gene switch architecture, 
a VEGF-A induction ratio of ~200× can be achieved in HEK293 cells at micromolar 
concentrations of DHB.  
 
In another example, we report the development of a system to assemble a multi-gene 
pathway and subsequently regulate the entire pathway in yeast using an estradiol gene 
switch. To demonstrate the utility of the system, we assembled the 5-gene zeaxanthin 
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biosynthetic pathway in a single step and showed the ligand dependent, coordinated 
expression of all 5 genes as well as the tightly-regulated production of zeaxanthin. 
 
In the second half, we will look into reprogramming via the modification of existing 
network components such as knocking-out or modifying specific genes on a cell’s 
genome. Site-specific genome editing relies on the ability to create double stranded break 
at the specific locus. The technique used for my works is based on transcription activator-
like effector (TALE) nucleases (TALENs), which allows researchers to design the DNA 
binding sequence through a simple cipher. In one example, we will discuss the 
development of a liquid phase high-throughput TALE synthesis platform (fairyTALE) 
capable of producing TALE-nucleases, activators, and repressors that recognize DNA 
sequences between 14 and 31 bp. It features a highly efficient reaction scheme, a flexible 
functionalization platform, and fully automated robotic liquid handling that enable the 
production of hundreds of expression-ready TALEs within a single day with over 98% 
assembly efficiency. We will also discuss the continued development of the fairyTALE 
platform to synthesize paired single-plasmid TALENs which opens up the possibility of 
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Chapter	  1:	  Introduction	  
1.1	   Cellular	  reprogramming	  
For the past hundred years, ever since the start of the biotechnology field, scientists and 
engineers have been trying to reprogram cells to do things that benefit human, such as 
producing drugs or food. We have made much stride towards that end, but until the more 
recent rise of metabolic engineering, which takes a closer look at the larger genetic 
network, most reprogramming works were limited to hijacking a cell’s protein expressing 
system (1).  
 
Central to the notion of cellular reprogramming is the idea that all cellular functions are 
part of a highly complex genetic and epigenetic network. Although much of this 
complexity is still unknown to us, we have nonetheless began exploring, perturbing, and 
creating genetic circuits in cells (2, 3). To truly understand and control a cell, we have to 
build it from scratch, but as of today, this remains a remote possibility (4). As oppose to 
the bottom-up approach, a top-down approach is what I have undertaken in my 
dissertation. Regardless of the route, the ultimate aim is the same – to be able to program 
cells like we do to robots today. 
 
Two general approaches will be discussed in this dissertation. In the first half, we will 
look into reprogramming via the introduction of external network components such as 
artificial transcription factor or pathway. In the second half, we will look into 
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reprogramming via the modification of existing network components such as knocking-
out or modifying specific genes on a cell’s genome. 
1.2	   Transcription	  factors	  
Over 300 distinct cell types can be found in the human body. They perform a diverse set 
of functions and adopt highly specialized structures, but they all share a single genome. 
This amazing feat is possible only through sophisticated gene regulations (5, 6). Gene 
regulation occurs at many levels, at the first level, epigenetics factors such as DNA and 
histone methylation regulate genes by controlling their accessibility (7, 8). At the second 
level, transcription factors regulate genes by controlling their transcription rates (9, 10). 
At the third level, combinations of mRNA processing and translation machineries 
regulate the production of gene products by controlling mRNA stability and translation 
rate (11, 12). Finally, gene products themselves can be regulated through processes such 
as allosteric interaction and phosphorylation (10, 13). 
 
Situated early in the chain of regulators, transcription factor is the first control point that 
offers both high spatial and temporal resolution. As the gatekeepers of genetic 
information, and they are powerful modulators of everything from life (metabolism (14)), 
growth (developmental patterning (15)), disease (oncogenesis (16)) and death (apoptosis 
(17)). The ability to engineer and control transcription factors is therefore an endeavor of 
fundamental importance and infinite potential. 
 
By definition, transcription factors are protein switches that control the flow of 
information from DNA to mRNA. Functionally, it can be divided into two classes – 
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activators and repressors. As their name implies, activators increase a gene’s transcription 
rate, whereas repressors decrease it. Structurally, most transcription factors are modular 
with at least two modular domains – the DNA binding domain recognizes and binds to a 
specific DNA sequence, and the activation domain recruits the transcriptional 
machineries to initiate transcription (9). Some transcription factors can also contain 
additional domains such as a ligand-binding domain that interacts with chemical signals 
(18). Gene switch is another name for transcription factor, and it makes its cellular 
function more apparent. The two terms are often used interchangeably.  
1.2.1	   Estrogen	  receptor	  alpha	  
The estrogen receptor alpha belongs to the nuclear receptor family of proteins. It is a 
ligand-inducible transcription factor that responds to estrogen and activates the 
transcription of a set of genes. The human estrogen receptor alpha (ERalpha) can be 
divided into 6 separate domains, classically indexed A through F (19, 20). The A/B 
domain is the transcriptional activation domain and is capable of ligand-independent 
activation. The C domain is the DNA-binding domain (DBD), which consists of two 
zinc-fingers recognizing the estrogen response element (ERE) (21). Since ERalpha 
functions as a dimer, the ERE is made up of two palindromic half-sites: AGGTCA NNN 
TGACCT (22). Domain D is a hinge domain that also participates in dimerization, 
nuclear localization, and co-activator binding (23).  Domain E is the ligand-binding 
domain (LBD), consisting of 12 alpha helices that form a hydrophobic ligand-binding 
pocket (24). The natural ligand is 17β-estradiol, but it is also capable of binding to a large 
number of other ligands (25). Some ligands, such as 17β-estradiol, activate ERalpha, and 
are known as an agonist (24), while others can inactivate ERalpha, among them, the most 
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notable antagonistic ligand is tamoxifen, which is used in the treatment of ER positive 
breast cancers (26). Lastly, Domain F is responsible for modulating the activity of 
ERalpha, and is involved in agonist and antagonist distinction (27). 
 
Figure 1.1 Estrogen receptor alpha domains. Amino acid position, domain index and function indicated. 
 
Without ligand binding, the ERalpha remains as a monomer and is bound to Hsp90 (28). 
Ligand binding triggers a conformational change that releases ERalpha from Hsp90, thus 
allowing it to dimerize (29). The dimer can now recognize the ERE and binds to ERE-
containing promoters. The activation domain, together with co-activators such as SRC-1, 
will then recruit the rest of the transcriptional machineries and start transcription (20). 
1.3	   Engineering	  gene	  switches	  
Due to the modular nature of transcription factors, the different domains can be 
exchanged to achieve chimeric function. As a corollary, the different domains can also be 
engineered independently to achieve a totally novel function.  
1.3.1	   DNA-­‐binding	  domains	  
The targeting specificity that a gene switch controls is determined by its DBD. By 
engineering DBDs that can bind specifically to the promoter of interest, the 
corresponding gene can be regulated by the gene switch. Traditionally, the Cys2-His2 
zinc finger DBD is the most frequently engineered DBD, and it is also extremely 
common in naturally occurring mammalian transcription factors (30, 31). Each Cys2-
!"#$ %$&$ '$ ($)*$ *&$
+$ +,-$ ./0$ 0-.$ 110$ 121$
!(*+$ %#%$ 34567$ 8#%"!(*.$
 5 
His2 zinc finger can recognize 3bp of DNA sequence. A collection of zinc fingers that 
recognize any conceivable DNA triplet can theoretically be used to construct zinc finger 
concatemers that recognize any DNA sequence (32, 33). In reality however, zinc fingers 
have strong preference for guanine, so the functional triplets are therefore mostly guanine 
rich, thus limiting the range of DNA sequences that can be targeted. Furthermore, zinc 
fingers are not entirely modular and inter-finger interaction can make zinc finger 
multimer functionally unpredictable (30, 34). By building a large collection of zinc finger 
monomers and dimers, and combine that with high-throughput screening capability, most 
of the difficulties, except target preference, can be alleviated. Currently, commercial 
custom zinc finger maker (Sigma Aldrich, St Louis, MO) can routinely produce zinc 
finger DBDs with an 18 bp recognition site. 
1.3.2	   Ligand-­‐binding	  domain	  
The LBD determines the chemical signal to which an inducible gene switch responds. 
However, most naturally occurring LBDs, as intended by nature, respond to endogenous 
ligands. When employed in its native host, the LBD will experience interference from the 
host’s ligands. For instance, if ERalpha LBD is used in a gene switch for a mammalian 
system, endogenous estrogen may activate the gene switch independent of external 
control. Furthermore, when exogenous estrogen is used to control the gene switch, it will 
inadvertently wreak havoc with the host’s endocrine system (25). It is therefore important 
to have orthogonal ligand-receptor pairs, so that the gene switch and its corresponding 
ligand can act orthogonally to the host’s system.  
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Two approaches can be taken to achieve orthogonality. In one approach, we can use a 
LBD from a heterologous origin that has no homolog in its intended host. For example, 
human ERalpha can be used orthogonally in yeast, and bacterial tetracycline repressor 
can be used orthogonally in human (35, 36). In the other approach, the LBD can be 
engineered to respond to new synthetic ligands to form novel orthogonal ligand-receptor 
pairs(37). 
1.3.3	   Activation	  domain	  
The activation domain determines how the gene switch interacts with the transcriptional 
machineries. The structural requirement for an activation domain is rather 
undiscriminating: (1) they often have an abundance of acidic residues, and (2) an alpha 
helix appears necessary (9). Given the lack of stringent criteria, activation domains are 
unsurprisingly promiscuous, i.e. if an activation domain works in one eukaryotic cell, it 
will likely work in many eukaryotic cells from any species (9). Two of the most 
commonly used eukaryotic activation domains are VP16 and VP64, both derived from 
the human herpesvirus (38). The activation domain can also be replaced by other 
functional domains such as a repression domains, which will create a ligand-inducible 
repressor instead of an activator (38).  
1.3.4	   Previous	  studies	  in	  Zhao	  group	  
The seminal works of previous lab members laid the foundation for my dissertation. First, 
Chockalingam et al. established a method to switch the ligand specificity of ERalpha. 
Based on the crystal structure of the ER LBD, 20 sites lining the ligand-binding pocket 
were chosen for saturation mutagenesis. After initial rounds of iterative saturation 
mutagenesis, the positive mutant was then subjected to random mutagenesis to further its 
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specificity and sensitivity. Through this method, he showed that novel orthogonal ligand-
receptor pairs can be systematically developed (37). Second, McLachlan et al. introduced 
the synthetic gene switch architecture, where an engineered zinc finger DBD, an 
engineered LBD, and a general acidic activation domain were fused to create an artificial 
transcription factor (39). He also demonstrated the use of orthogonal gene switches in 
gene circuit construction using ligand-inducible activators and repressors (40).  
1.4	   Applications	  of	  gene	  switches	  
In the first part of this dissertation, I will address the continued development of the gene 
switch architecture for endogenous gene regulation and exogenous gene regulation. 
1.4.1	   Endogenous	  gene	  regulation	  
The ability to control endogenous genes has applications in gene therapy and biological 
research. In cases where a disease state is caused not by the total lack of a gene, but 
rather, by the uncoordinated or unsynchronized production of a gene product, regaining 
control over the endogenous gene locus could be an equally if not more effective solution 
than simply inserting another copy of the gene. Controlling the expression of endogenous 
genes can also be a valuable tool for interrogating fundamental biological questions. The 
high temporal control of gene switches allows researchers to turn on or off a gene of 
interest at a desired time point so that its effect can be studied.  
1.4.2	   Exogenous	  gene	  regulation	  
When exogenous genes are introduced into a host, indiscriminate overexpression will 
often lead to counter productivity. The logic is obvious when the gene products or the 
biosynthetic pathway products are toxic to the host, but it is also true for non-toxic 
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products.  If the product interacts with the host’s genetic network, indiscriminate 
overproduction will lead to imbalance and poor overall fitness. Even when there is no 
direct interaction, channeling energy and metabolites aimlessly to overproduction is a 
futile exercise for the host. It is therefore often desirable to put any introduced genes 
under the control of an inducible production system. 
1.5	   Genome	  editing	  with	  TAL	  effectors	  
Instead of introducing external network components to a cell, we can also modify a cell’s 
native network components to achieve reprogramming. Genome editing technology 
includes the knockout, deletion, insertion, or replacement of specific loci on a cell’s 
genome (41). Regardless of the tool employed, the general process involves first creating 
a double-stranded break on the DNA loci of interest, and then making one of the above-
mentioned modifications through either non-homologous end joining or homologous 
recombination (42). TAL effector nucleases are among the most popular tools for 
creating locus-specific double stranded breaks (43), and they will be the focus of my 
dissertation. 
1.5.1	   General	  structure	  
Transcription activator-like (TAL) effectors were first discovered in Xanthomonas, a 
plant pathogen (44). TAL effectors (TALE) were used by the bacteria to alter the host’s 
genetic circuit so as to mediate its own propagation (45). The DNA recognition code of 
TALE was discovered in 2009 (46, 47), following which, an explosion of TALE based 
genome editing technologies soon followed (48). 
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Figure 1.2  Structure of a typical TALE. The N-terminal extension contains a secretion signal (SS) 
necessary for translocation via the type III secretion system in Xanthomonas. The central repeat domain is 
the main DNA binding domain (DBD) and is responsible for DNA specificity. The C-terminal extension 
contains a nuclear localization signal (NLS), and a transcriptional activator domain, both intended to 
function in the plant host. 
 
A typical TALE can be divided into 3 domains, namely the N-terminus extension, the 
central repeat domain (CRD), and the C-terminus extension. Although the N- and C-
terminus extensions do not appear to contribute to a TALE’s binding specificity, they are 
nonetheless essential for TALE binding. Crystallographic data suggests that the N-
terminus is more rigid than the C-terminus (49, 50). Furthermore, it has been suggested 
the rigid N-terminus in facts recognizes a thymine base 5’ to the CRD recognition 
sequence (51). 
 
The CRD determines the binding specificity of the TALE, and it consists of multiple 
repeats of a 34 amino acids (aa) motif (46, 47). These repeats are nearly identical except 
at aa 13 and 14, which is known as the repeat variable diresidue (RVD), and it determines 
the DNA binding specificity of the given repeat. There is a simple DNA binding code for 
the RVD – NI (Asp-Ile) for adenine, NG (Asp-Gly) for thymine, HD (His-Asp) for 
cytosine, NH (Asp-His) for guanine, and NN (Asp-Asp) for either guanine or adenine 
(52). Although the NH RVD exhibits better specificity for guanine, the NN RVD appears 













methylated cytosine in a CpG island by using the NG RVD(54). An engineered TALE 
typically contains between 12 to 30 of these repeats(55). 
 
Natively, TALEs are transcription activators with a plant nuclear localization signal and a 
transcription activator domain on the C-terminal end (44). When used in genome editing, 
these functional domains are replaced by a FokI DNA cleavage domain, and the resulting 
construct is called a TALE nuclease (TALEN) (43). Other than being a nuclease 
however, other functional domains such as transcriptional activators (56), ligand-binding 
domains (57), recombinase domains (58), or hydroxylase domain(59) can be attached to 
TALEs to make artificial site-specific transcription factors, recombinases, and DNA 
demethylases respectively. 
1.5.2	   Previous	  studies	  in	  Zhao	  group	  
The TALEN architecture used for my work was first developed and optimized by Sun et 
al. in Zhao group (60). After which, Sun further improved the DNA cleavage efficiency 
of the FokI cleavage domain by directed evolution (61), and achieved over two-folds 
activity improvement over the wild-type FokI domain in human cells. This improved 
FokI domain has also been incorporated into all my work. 
1.5.3	   Assembly	  methods	  
Being a highly repetitive protein, the TALE was very difficult to modify. Early on in the 
development of TALE genome editing technologies, multiple groups developed TALE 
assembly methods to help researchers with its construction (62-65). However, due to the 
requirement for multiple rounds of cloning, the through-put of these early methods were 
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low, and the demand of high-throughput TALE synthesis spurred the development of 
multiple 1-step synthesis methods with varying capabilities (66-70).  
 
Current methods for high-throughput TALE DBD synthesis methods can be divided into 
three categories: solid phase synthesis(66, 67), ligation-independent synthesis(68) and 
liquid phase synthesis(69, 70). Solid phase synthesis involves the attachment of the 
growing DNA on a solid support and elongation is carried out by sequential enzymatic 
ligation. Due to the sequential nature of the elongation step, these methods generally have 
high reagent cost. Ligation-indepdent synthesis involves the annealing of long 
overlapping overhangs to link fragments together. However, limited by the number of 
fragments that can be linked simultaneously at high efficiency, this method requires a 
very large substrate library (>3000 substrate plasmids). Liquid phase synthesis involves 
the simultaneous ligation of all the necessary fragments via Golden Gate assembly(71). 
The ability to ligate more fragments in one reaction help limits both the substrate library 
size as well as reagent cost. Despite the options available, all the methods so far required 
a clonal isolation and verification step that remained a bottleneck in the downstream 
process. 
1.6	   Project	  overview	  
In the first part of this dissertation, I will show two applications of genetic regulation 
using gene switches – first an example of endogenous gene regulation in human cells, 
then an example of exogenous gene regulation in yeast. In the second part of this 
dissertation, I will dive into the use of TALE for genome editing applications, with a 
focus on high-throughput TALE and TALEN synthesis. 
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Chapter 2 describes the ligand-inducible activation of endogenous vascular endothelial 
growth factor A (VEGF-A) in a human cell line. VEGF-A is an important signaling 
molecule in angiogenesis, and it plays a significant role in growth, recovery as well as 
disease. Using an engineered LBD and optimized single-chain gene switch architecture, 
endogenous VEGF-A can be induced, by an orthogonal synthetic chemical ligand, up to 
250-folds, which is among the best endogenous gene activation reported in literature. We 
further demonstrate that VEGF-A expression can be tightly and reversibly controlled, 
thus enabling an easily customizable dosage profile that is important for proper 
angiogenesis. This gene switch architecture can serve as the template for developing 
future gene switches to target any endogenous gene. 
 
Chapter 3 describes the development of a coordinated induction system for expressing 
heterologous multi-gene pathways in yeast. Using an ERalpha based gene switch in 
combination with a set of auxiliary strains and plasmids, multi-gene pathways can be 
easily assembled, and the resultant pathways are inducible by estrogen. As oppose to 
galactose, estrogen can be used in the presence of glucose, thus enabling the direct 
addition of estrogen to a culture without media change. Due to the exceptional sensitivity 
of ERalpha, only a minute quantity of estrogen is required to fully activate a large 
culture, making this a highly cost-effective method for industrial scale induction.  
 
Chapter 4 describes the development of a high-throughput TALE synthesis platform 
capable of producing expression-ready TALE in as little as one day. Using a robotic 
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liquid handling system, hundreds of TALE can be synthesized this way at a low cost of 
just $5 per TALE. After various process optimizations, we have achieved a very high 
construction fidelity of about 98%, and we show that we can skip clonal isolation without 
affecting the functional characteristics of the resulting plasmids. We have validated the 
method by making 90 TALENs and verifying their activity in yeast using a yeast reporter 
system. 
 
Chapter 5 describes the continued development of the high-throughput TALE synthesis 
platform described in Chapter 4. Because TALENs function as a heterodimer, a pair of 
TALEN is required to make a single cut. This need for a matched partner makes library 
transformation impossible. Here, we show the progress we have made towards the 1-step 
assembly of a single-plasmid TALEN construct. The single-plasmid TALEN construct 
can be assembled at a very high fidelity, and we have shown that it is functional in 
HEK293 cells and human stem cells.  
1.7	   Perspectives	  
The recent years have been an exciting time for genome engineers as we see multiple 
genetic control and modification tools burst into the scene. In spite of the progress, we 
are still far from understanding the complexity of life. Concealed under the elegant 
simplicity of the cell, are intricate complexities that have refined over billions of years of 
evolution. To program a cell with neither a complete understanding of how it functions 
nor the ability to build one from scratch, we are confined to taking a top-down approach 
in our endeavor. 
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The multitude of tools and strategies required to totally control complex cellular 
functions, are beyond the scope of my dissertation or perhaps even my scientific career. 
Here, we have touched on two important technologies used in cellular reprogramming – 
controlling gene expression using artificial transcription factors, and making specific 
genome modifications using TALEN. Even though I have only shown how they can 
modify cellular behavior each separately in isolated context, the true power lies in the 
combination of multiple techniques in an orchestrated synchrony. I hope we will see such 
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Chapter	  2:	  Orthogonal	  control	  of	  endogenous	  gene	  expression	  in	  
mammalian	  cells	  using	  synthetic	  ligands	  
2.1	   Introduction	  
Since their inception, small-molecule controlled transcription regulators, or gene 
switches, have been powerful tools in many areas of biological and biomedical sciences.  
For example, in developmental biology, signaling pathways can be dissected through 
temporal suppression and expression of genes within the pathways.  In gene therapy, the 
induction of a beneficial gene product can be regulated to fall within a therapeutic 
window or ceased when necessary (1-4).  With the advent of synthetic biology, complex 
gene circuitries can be built from a set of well-behaved gene switches, thus creating 
further demand for orthogonal gene switches (5, 6).  In addition, there is a growing 
interest in controlling complex phenotypes, especially in mammalian cells.  Controlling 
complex phenotypes requires the remodeling of an intricately interconnected genetic 
network.  Due to the network’s size and complexity, many cellular phenotypes are 
inaccessible via the control of a single gene locus.  For example, the induction of 
pluripotency in human somatic cells requires the simultaneous induction of at least three 
genes (7-9).  To maximize the control over the genetic network, it is highly desirable not 
only to control multiple genes at the same time, but also to control them using 
independent orthogonal ligands.  
 
The aim of this chapter is to develop a framework for the engineering of orthogonal 
mammalian gene switches, and demonstrate its utility through the ligand-dependent 
induction of an endogenous gene. Compared to typical multi-copy plasmids, genes on the 
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chromosome has a much lower copy number, and the induction of endogenous loci is 
often more challenging, therefore placing higher requirement on the efficiency of the 
design.  Induction of endogenous genes is of particular interest in mammalian systems 
because its gene products have shown better therapeutic efficacy compared to those of an 
exogenous gene, possibly by providing the necessary splice variants (10).  Such 
functionality will also be useful to developmental biology and synthetic biology because 
it sometimes takes multiple splice variants working in tandem to achieve a desired 
biological effect (10).  
 
Tetracycline receptor, ecdysone receptor, chemical dimerizers, and nuclear hormone 
receptor are among the leading platforms for mammalian gene regulation (4).  In this 
chapter, we focus on the nuclear hormone receptor platform because (a) the protein can 
be fully humanized, which minimizes the chance of immune response, (b) the ligand 
specificity can be engineered and changed to create orthogonal ligand-receptor pairs, and 
(c) its modular design allows convenient change of its DNA binding domain to target 
different genes.  Under the nuclear hormone receptor platform, the ligand-binding 
domain from a nuclear hormone receptor, e.g. estrogen receptor and progesterone 
receptor, is fused with a zinc-finger DNA binding domain that binds to the promoter 
region of the target gene.  Although estrogen receptor itself has slight activation ability, 
an activation domain, e.g. VP16, VP64, or p65, is typically added to enhance its 
induction power (11). 
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The ligand-induced regulation of endogenous genes has been previously demonstrated 
using such a gene switch platform (12, 13).  However, two main shortcomings currently 
limit the utility of this platform.  First, the ligands used for induction are not orthogonal 
to natural occurring nuclear hormone receptors, and have potent biological effect in 
mammalian systems.  Second, the basal expression from the platform is considered 
somewhat leaky compared to the tightly controlled tetracycline receptor platform.  This 
can be due to the natural occurrence of hormones in the mammalian system or the 
presence of an ectopic overexpression of an activation domain.  In a recent study, 
Schwimmer et al. have partially addressed the first problem through the development of a 
benzoate X receptor gene switch (14).  However, this has yet to be demonstrated in an 
endogenous context. 
 
Figure 2.1 The structure of 17β-estradiol (E2), the natural ligand of estrogen receptor (ER), and the 
structure of 4,4-dihydroxybenzil (DHB). 
 
In this study, we aim to address these main limitations.  To create orthogonality, we 
utilized a previously engineered estrogen receptor ligand binding domain (LBD) that is 
sensitive to 4,4-dihydroxybenzil (DHB) – a synthetic non-steroid ligand that acts 
orthogonally to estrogen (Figure 2.1) (15, 16). The LBD consists of amino acids 312-595 
of the human estrogen receptor alpha, and the engineered version, called 4S LBD, has 
mutation A350M, L346I, M388Q, G521S, Y526D. DHB is synthetic ligand that is 
E2 DHB 
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structurally similar to diethylstilbestrol, a FDA approved drug, and it has been shown to 
have low cytotoxicity in cell culture and low systemic toxicity in mouse model (15, 17).  
 
The vascular endothelial growth factor A (VEGF-A) was chosen as a model target for 
this study.  VEGF-A is an important signaling molecule in angiogenesis, and its 
regulation has many therapeutic applications (18).  For example, the up-regulation of 
VEGF-A can help new blood vessels formation as a treatment for ischemia, whereas the 
down-regulation of VEGF-A can restrict the growth of tumors (19, 20).  To target the 
endogenous VEGF-A loci, we have utilized VZ-8, a zinc-finger DNA binding domain 
(DBD) engineered by Liu et al., which recognizes a 9 base pairs site within the VEGF-A 
promoter, and has been shown to activate VEGF-A expression when combined with an 
activation domain (21).  
 
In this work, we have combined the VZ-8 DBD, the 4S LBD, and the p65 activation 
domain to make our gene switch. The human p65 protein is part of the NF-κB activation 
complex (22).  It is 551 amino acids (aa) long and most of the activation activity is 
localized at the C-terminal region (23). To minimize basal expression level and maximize 
induction level, we performed domain length optimization of the p65 activation domain, 
as well as domain permutation and linker optimization of the overall architecture.  
 
When transiently transformed into HEK293 cells, our construct in the absence of DHB 
showed no VEGF-A expression beyond the normal basal level.  When induced with 1 
µM DHB, a 170-fold increase in VEGF-A expression was observed.  This induction was 
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roughly twice as high as that achieved with a constitutive construct.  When stably 
integrated into HEK293, >250-fold induction was observed with no detectable basal 
expression.  This gene switch has among the highest performance characteristics as 
compared to previously reported endogenous gene induction studies.  Furthermore, it 
provides the architecture to combine the zinc-finger DBD technology with the ligand 
specificity engineering technology, and brings us one step closer to the ability to control 
multiple genes with multiple orthogonal ligands. 
2.2	   Results	  
2.2.1	   Domain	  permutations	  
We attempted to use our gene switch to induce the endogenous VEGF-A expression in 
HEK293 cell line.  HEK293 was chosen in the induction study because of its low basal 
VEGF-A level, and its widely reported use in endogenous VEGF-A induction studies (13, 
21, 24).  Our initial construct, p65-VZ8-4S, did not show any induction activity.  We 
proceeded to try a set of different domain permutations as listed in Figure 2.2a.  The last 
two dual LBD single-chain constructs, V24P and P24V, were by far the best performing 
constructs, outperforming the rest by at least 5 fold (Supplementary Figure A.1). 
 26 
 
Figure 2.2 Diagrammatic representations of the constructs used in this study.  All constructs were cloned 
into pCMV5 for transient expression and pLNCX2 for stable integration.  P65 is the p65 activation domain 
of NF-κB.  VZ8 DBD is the VZ-8 zinc-finger DNA binding domain that binds within VEGF-A promoter.  
4S LBD is an engineered ER ligand binding domain that is activated by DHB.  (a) Variations of gene 
switch used in the initial screening to identify the best architecture.  (b) Linker length optimization 
construct based on V24P. 
 
2.2.2	   Single-­‐chain	  gene	  switch	  optimization	  
The estrogen receptor LBD dimerizes during the process of ligand activation, and it has 
been shown that a single-chain estrogen receptor – comprised of two LBDs fused 
together – can activate gene expression by intramolecular dimerization (12, 25).  Since it 
was unclear how two chimeric estrogen receptor gene switches would dimerize, we 
postulated that the linker length between the LBDs could affect dimerization and thus its 
activation characteristics.  A set of single-chain gene switches from the V24P and P24V 
constructs was constructed by inserting between the two 4S LBDs varying lengths of GS 
linkers (G4S)n ranging from 20 to 110 aa long (Figure 2.2b).  This set of gene switches 
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was transiently expressed in HEK293 cells under the CMV promoter, and the VEGF-A 
concentration was assayed by ELISA 24 hours after DHB induction.  
 
Figure 2.3 Endogenous VEGF-A induction in transiently transfected HEK293.  (a) The horizontal axis 
labels represent the constructs’ names, and the V24P series contain GS linkers ranging from 0 to 110 amino 
acids long.  White bar is uninduced, and grey bar is induced with 1 µM DHB.  VZ8-P65 is a constitutive 
positive control and F435P is a positive control obtained from Bae et al. (26) to serve as a performance 
yardstick.  EGFP, Gal-P65, and Gal-P65 + DHB are negative controls.  Error bar represents standard error, 
and measurements have been obtained from two separate transfections, each assayed in duplicate.  The y-
axis is truncated to allow clearer representation of the uninduced level.  (b) Time response profile obtained 
by adding ligands to wells at 1-hour intervals for 12 hours. 
 
As shown in Figure 2.3a, it was found that in the V24P construct, induction level peaked 
with a 60 aa linker, which offered a 20% improvement over the construct with no linker.  
Furthermore, the basal expression level decreased with increasing linker length, 
bottoming out also at 60 aa.  The induction ratio for V24P-GS60 was about 170-fold.  A 
peak induction level of 2456 pg/mL was achieved, which was significantly higher than 
even the constitutive constructs VZ8-P65 and F435P.  The basal level was around 13 
pg/mL, lower than the EGFP negative control, but higher than the Gal-P65 negative 
control.  VZ8-P65 consists of a VZ8 DBD fused directly to a p65 activation domain, and 
served as constitutive activator of VEGF-A, whereas F435P is another zinc-finger based 
constitutive activator of VEGF-A obtained from Bae et al. (26), and served as a 











































































benchmark for the observed induction level.  Gal-P65 consists of a Gal4 DBD fused 
directly to a p65 activation domain, and served as a control for any non-specific induction 
caused by ectopic expression of p65. 
 
The P24V construct offered a different profile of activation.  While the induction level 
appeared independent of linker length, the basal expression level increased with 
increasing linker length.  The strength of induction of the P24V construct was less than 
half that of V24P, but the basal level for P24V was only 3 pg/mL (outside of standard 
curve), which was comparable to the Gal-P65 negative control.  The very low basal 
expression gave the P24V construct an induction ratio of 300-fold despite its lower peak 
induction level.  
2.2.3	   Time	  response	  
The speed of activation is an important gene switch parameter.  Being a constitutively 
expressed single-step transcriptional switch, it is expected to be slower than translational 
switches, but comparable to that of a Tet-On system controlling a transgene (27).  To 
characterize the response time of the gene switch, we added DHB to identical wells at 
one-hour intervals, and assayed their VEGF-A concentration at the end of 12 hours 
(Figure 2.3b).  VEGF-A production was clearly detectable from 3 hours onwards, and 
increased steadily thereafter. 
2.2.4	   Ligand	  response	  
V24P-GS60 was chosen for further characterization because of its high induction power, 
and we hypothesized that the basal level could be reduced with lower gene switch 
expression level.  For further characterization, the P24V-GS60 gene switch was 
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integrated into the chromosome of HEK293 via retroviral integration and antibiotic 
selection.  At first, single-clone isolation was not carried out because we wanted to see 
how the integrated switch behaved in aggregate, given that individual clones vary in their 
performances.  
 
Figure 2.4 Ligand titration curve obtained using HEK293 cells stably integrated with V24P-GS60 gene 
switch.  Error bar represents standard error, and measurements have been obtained from two independent 
wells, each assayed in duplicate.  (a) Ligand titration curve of a heterogeneous integrant population. Black 
square series represents the measured, un-normalized, VEGF-A values.  The cell number at the time of 
sampling was used to normalize the grey circle series.  (b) Ligand titration curve of a highly inducible 
clonal integrant population, which was fitted to a Hill curve.  Min = 108, Max = 4588, Hill Coefficient = 
2.3, Km = 38 nM, R2 = 0.9996.  (c) A representative series of ligand titration curves with shifted Km.  (d) A 
fit of the observed heterogeneous ligand titration curve using the series in (c) as a basis set, R2 = 0.9978. 
 
Compared to the plasmid version, the integrated version was slightly less sensitive to the 
ligand, possibly due to a lower gene switch expression level from the reduced copy 
number per cell.  An induction level of 1895 pg/mL was achieved at 1 µM DHB and 


































































































2519 pg/mL was achieved at 10 µM DHB, giving an induction ratio of ~250-fold (Figure 
2.4a).  The induction appeared to taper off at 10 µM, but cell numbers were significantly 
less at high inducer concentration.  Therefore, the cell number was counted at the time of 
sample collection and normalized by the measured VEGF-A level.  It was found that, 
after normalization to cell number, there was no attenuation of induction up to 10 µM 
DHB.  However, increasing the ligand concentration beyond 10 µM was impractical due 
to severe impairment on cell growth.  The growth impairment most likely came from the 
heavy metabolic burden under high induction, because no effect on cell growth could be 
observed in cells not expressing the gene switch, even after prolonged DHB and/or 
VEGF-A exposure. The induction was log-linear to ligand concentration over at least 2 
orders of magnitude.  This characteristic allowed the switch to be tuned by external 
ligand concentration and achieve induction of different strengths.  
 
Despite its usefulness in fine-tuning gene expression, a gently sloped ligand titration 
curve was atypical for a 4S LBD gene switch (15).  Suspecting that this observation 
might be an aggregated behavior, 12 clonal cell lines were isolated from the 
heterogeneous population, and tested for their VEGF induction level at 1 µM DHB.  The 
induction level ranged widely from 810 to 5100 pg/mL, and the average of the 12 clonal 
cell line was 2740 pg/mL, which was close to that obtained from the whole 
heterogeneous population (Supplementary Figure A.2).  When we picked the most 
inducible clone and performed a ligand titration, we obtained a nearly perfect sigmoidal 
response with a Hill’s coefficient of 2.3, and a Km of 38 nM (Figure 2.4b).  Further tests 
on other clones reflected that the Km varies between clones (Figure 2.4c).  
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We propose that the ligand titration curve of the heterogeneous population is a weighted 
sum of a series of perfectly sigmoidal curves with different Km.  As seen in Figure 2.4d, 
using just 8 evenly spaced sigmoidal curves as the basis set, we can fit the observed 
heterogeneous ligand titration curve very well by assigning different weightage to them. 
2.2.5	   Sustained	  induction	  and	  reversal	  
In some applications, long-term sustained induction might be required, whereas in other 
applications, short intervals of repeated induction might be preferable.  To characterize 
the long-term induction, induction reversal, and repeated induction behavior of the gene 
switch, the stably integrated HEK293 cells was subjected to three 16-day time courses 
(Figure 2.5).  The first set of experiments was performed using the heterogeneous 
population of integrants.  In time course 1, the cells were induced for 2 days followed by 
6 days of rest; in time course 2, the cells were induced for 4 days followed by 4 days of 
rest; and in time course 3, the cells were maintained at 1 µM DHB through the entire 
duration.  All values were normalized to the cell number at the time of sampling. 
 
In time course 1 (Figure 2.5a), the VEGF-A production level increased quickly to about 
2700 (pg/mL/24h) one day after ligand addition, and increased further to 3700 
(pg/mL/24h) on the second day.  The VEGF production decreased quickly upon ligand 
withdrawal, reaching basal level in two days.  When the cells were re-induced on day 9, a 
similar behavior was observed.  This showed that the induction was reversible and 
repeatable.  In time course 2 (Figure 2.5b), the daily VEGF-A production level increased 
initially for 3 days, reaching up to 4800 (pg/mL/24h).  However, VEGF-A production 
 32 
dropped on the 4th day despite continued induction.  The induction sensitivity was only 
partially recovered after 4 days of rest, and a drop in induction level was still observable 
on the 4th day of re-induction.  During sustained induction in time course 3 (Figure 2.5c), 
a similar trend was observed for the initial 3 days of induction.  The induction level then 
decreased steadily from the 4th day onwards.  After 15 consecutive days of induction, the 
VEGF-A production level dropped to near basal level.  
 
Figure 2.5 Time courses obtained using HEK293 cells stably integrated with V24P-GS60.  Error bars 
represent standard errors, and measurements have been obtained from two wells, each assayed in duplicate.  
Values have been normalized by the cell number at the time of sampling.  Media (and ligand) was changed 
24 hours prior the each sampling.  (a) Heterogeneous time course 1, induced for 2 days at 1 µM DHB, 
rested for 6 days, repeat.  (b) Heterogeneous time course 2, induced for 4 days at 1µM DHB, rested for 4 
days, repeat.  (c) Heterogeneous time course 3, sustained induction at 1 µM DHB.  (d) Clonal population 
time course, sustained induction at 20 nM DHB with 200 nM spikes on day 1 and day 9. 
 
It was found that sustained induction could only be maintained using a clonal integrant 
cell line, and at such a level that it does not affect cell growth.  The sustained induction 






































































































time course was repeated using a highly sensitive clone at 20 nM DHB, which 
corresponds to an induction level of about 1000 (pg/mL/24h).  At this level, the induction 
can be sustained for the entire duration of the time course (Figure 2.5d).  To demonstrate 
that the cells were still capable of high induction, the maximum induction of 5500 
(pg/mL/24h) was elicited using 200 nM DHB on day 1 and again on day 9.  
2.2.6	   Localization	  
Because of the low VEGF-A background in our test cell line, we were unable to 
determine if the presence of the un-induced gene switch had any effect on the VEGF-A 
expression.  It was plausible that the DNA binding domain could still bind to the 
promoter and affect native transcription.  To test this possibility, a localization study of 
the gene switch was performed, i.e. if the gene switch were mostly cytosolic when un-





Figure 2.6 Confocal microscopy study.  
Fluorescent gene switch constructs are 
created by inserting EGFP at the N-
termini of the gene switch constructs 
used for transient expression.  The 
EGFP constructs are transfected into 
HEK293 cells grown on Ibidi poly-D-
lysine µ-slide (Ibidi, Verona, WI) using 
FuGene HD (Promega, Madison, WI).  
Images are taken 24 hours later using 
Carl Zeiss LSM 700 confocal 
microscope (Thornwood, NY).  Nucleus 
stain channel shows the nuclei counter 
stained by Hoechst dye (Invitrogen, 
Carlsbad, CA).  EGFP channel shows 







The EGFP gene was fused to the N-terminus of our gene switch and confocal microscopy 
was used to visualize where the gene switches were localized in the cell (Figure 2.6).  To 
ensure the EGFP-fused gene switch would behave similarly, its induction activity was 
also assayed.  The activity data showed that the EGFP fusion protein was active, albeit at 
a lower level most likely due to a reduced expression level. 
 
The confocal images indicated that the gene switch was mostly localized within the 
nucleus with and without ligand.  The natural estrogen receptor is known to reside mostly 
in the nucleus and the presence of an engineered ER LBD alone appears sufficient to 
confer this localization property.  For natural full length ER, the un-induced receptor is 
bound to heat shock protein (hsp90), which prevents dimerization and blocks the 
transcription regulation activity of the receptor.  In contrast, it has been reported that the 
ER LBD alone is insufficient for binding to hsp90 (28).  Whether this is true for our 
engineered gene switch remains to be tested.  
 
2.3	   Discussion	  
In this chapter, we have demonstrated that our gene switch is able to induce endogenous 
VEGF expression in HEK293 cells using a non-steroid orthogonal ligand.  An induction 
ratio of over 100-fold can be achieved at µM ligand concentration.  We have also shown 
that the induction is fast, reversible, and sustainable as long as the cellular machinery can 
support it.  
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To highlight the performance of our gene switch, it is important to make some cross 
comparisons with the performance of previously reported gene switches.  This is, 
however, difficult due to differing assay conditions.  We have summarized previously 
reported VEGF induction values, be it inducible or constitutive, and made reasonable 
comparisons whenever possible (Figure 2.7).  Overall, our gene switch assay has among 
the lowest initial cell number and among the shortest accumulation time, and yet, has the 
highest peak VEGF induction value.  Pollock et al. normalized their VEGF assay by total 
cellular protein content, and is therefore not directly comparable (29).  Fortunately, both 
Pollock et al. and Liu et al. have included hypoxia positive control which suggests that 
Pollock’s assay conditions yield values roughly 8.5 times that of Liu’s (21, 29).  Liu’s 
and Dent’s studies share a common construct, VZ+434-P65, and their relative value 
suggests that Dent’s assay yields values roughly 3.5 times that of Liu’s (13, 21).  Our 
study shares a common construct with Bae et al., F435P, which suggests that Bae’s assay 
yields value roughly twice ours (26). 
 
Figure 2.7 Comparison of assay conditions and induction values in previously reported VEGF-A induction 
studies.  When a particular condition or construct is shared between studies, the name and value is noted 
under Reference Values. *Not specified, assume typical working volume for the plate format. 
 
Author Liu et al. Pollock et al. Bae et al. Dent et al. This Work 
Cell Line HEK293 HEK293 HEK293 HEK293 HEK293 
Seed Density 1.60 x 105 3.00 x 105 1.00 x 105 Unknown 8.00 x 104 
Format 24-well 12-well 12-well Unknown 24-well 
Volume 500!L* 1mL* 1mL Unknown 500!L 
Accumulation Time 40h 48h 48h 24h 24h 
Peak VEGF value 700 5000 2200 1800 2500 
VEGF unit pg/mL pg/mg pg/mL pg/mL/24h pg/mL/24h 
Induction Type Constitutive Inducible Constitutive Inducible Inducible 
ELISA Kit R&D Systems R&D Systems Chemicon R&D Systems R&D Systems 
Reference values Hypoxia Hypoxia F435-P VZ+434-P65 F435-P 
400 3500 2200 2500 1100 
VZ+434-P65 
700 
Table 1 – Performance Comparison 
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Taken together, our gene switch produces the highest peak induction value as well as the 
highest induction ratio, even when compared with constitutive constructs.  It should be 
noted that induction ratio is highly dependent on basal level expression, and due to the 
low basal level expression under non-induction condition, our low-end measurement 
values are often too close to the detection limit of the ELISA assay to be dependable.  
This is especially true in the case of an integrated gene switch in a heterogeneous 
population, where the measured VEGF-A value is effectively zero.  In that case, we have 
used the ELISA detection limit (around 10 pg/mL) to calculate the induction ratio.  We 
have excluded from comparison the clonal assays value, which has a peak of 4588 
pg/mL, because it varies between cell lines and we do not believe that it is a good 
representation of the gene switch’s performance. 
 
In the presence of the uninduced gene switch, the basal VEGF-A level appears lower than 
the negative control.  This is the most pronounced in the integrated HEK293 cell line.  
Since our localization study found that the gene switch resides mostly in the nucleus with 
and without induction, it is possible for the DBD to bind and disrupt regular transcription.  
However, due to the high uncertainty associated with low value measurements, we are 
unable to determine if the un-induced gene switch represses VEGF-A transcription. 
 
We have shown that the induction is reversible and repeatable.  However, we are unable 
to sustain the induction over a long period of time in a heterogeneous population.  This is 
because cell growth is inhibited and cell death is triggered at a high induction level, most 
likely due to overwhelming metabolic burden.  Since the heterogeneous population 
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contains cell lines that have a wide range of ligand sensitivity, we are effectively 
enriching the non-secreting and low-secreting cells by killing off the highly inducible 
ones.  In a clonal cell line, induction is sustainable at a level that does not affect cell 
growth.  Unfortunately, this is achieved at a ligand concentration that is around the Km, 
where the induction level is most sensitive to minute differences in ligand concentration, 
thus leading to large errors of measurement. 
 
We also see important differences in the behavior of the heterogeneous and the clonal 
integrant populations.  For example, the ligand response curve is much gentler in a 
heterogeneous population which allows for finer control of induction level.  
Theoretically, by mixing a finite set of clonal population of different ligand sensitivities, 
we can tune the ligand response curve of the mixed population to achieve a sensitivity we 
desire.  
 
As a ligand, DHB has shown very little toxicity in multiple cell lines, with IC50 greater 
than 100µM (30). Similarly, DHB has also been found to have low systemic toxicity in 
mice, and intraperitoneal (IP) injection of 1 mg/kg is well tolerated. While DHB is stable 
in cell culture media for days, it is either rapidly cleared from or modified in mice with 
no detectable DHB remaining in blood 24h after IP injection. Despite the apparent short 
half-life, DHB has been successfully used to trigger recombination in mice through a 
Cre-ER fusion protein. The recombination efficiency observed using the DHB-4S ligand-
receptor pair was comparable to that of the tamoxifen-ERT pair (17, 31). 
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2.4	   Conclusions	  and	  outlook	  
To conclude, we have reported the design and construction of a highly effective ligand-
responsive artificial transcription factor whose performance tops previously reported 
designs.  This study represents the missing link between gene targeting technology and 
ligand specificity engineering, thus making it possible to create multiple orthogonal gene 
switches under the control of multiple orthogonal ligands.  This technology can be 
immediately useful to developmental biologists, and with further development, be useful 
in gene therapy and synthetic biology applications. 
 
The ultimate aim of the technology developed in this study is to create a platform for the 
engineering of orthogonal gene switches that can independently control multiple genes in 
mammalian systems.  The LBD used in our study is responsive to DHB and more 
orthogonal LBD-ligand pairs can be created through the established method published 
earlier.  In fact, the method has already been successfully applied in multiple studies, 
giving rise to multiple orthogonal LBD-ligand pairs (15, 16, 32).  In order to control 
multiple genes, multiple DBDs also need to be engineered.  Fortunately, zinc-finger DBD 
technology is well established and is now even commercially available (26, 33-35).  
Looking further, TAL effector DBD is a new class of DBD that promises even better 
modularity than zinc-finger DBD (36, 37).  However, its incorporation into the gene 
switch construct will likely involve redesign and optimization. 
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2.5	   Materials	  and	  methods	  
2.5.1	   Construction	  of	  gene	  switch	  
The P65 gene segment was PCR amplified and cloned from human cDNA and the 
different truncations were subsequently generated by PCR.  The engineering of the 4S 
ligand-binding domain was described elsewhere (15).  The VZ8 DNA binding domain 
was constructed by overlap extension of DNA oligos as described elsewhere (21).  The 
long GS linker was constructed by overlap extension PCR and the truncations 
subsequently generated by PCR.  The different parts were assembled using unique 
restriction sites introduced in the PCR primers, and cloned into pCMV5 for transient 
expression and into pLNCX2 for stable integration.  A list of plasmids used in this work 
can be found in Supplementary Figure A.3. 
2.5.2	   ELISA	  assay	  
HEK293 cell line was obtained from Professor Jie Chen of University of Illinois and 
propagated in DMEM (UIUC Cell Media Facility) with 10% FBS at 37ºC 5% CO2.  48 
hours before sampling, 8x105 cells were seeded into each well of a 24-well plate 
(PureCoat Amine, BD Biosciences).  36 hours before sampling, cells for transient 
expression were transfected by FuGene HD (Promega, Madison WI) according to the 
manufacturer’s recommendation using 500 ng of the appropriate gene switch plasmids.  
30 hours before sampling, ligands were added to appropriate wells.  24 hours before 
sampling, media was changed, and ligands re-added.  After 24 hours of accumulation, the 
supernatant was collected and assayed in duplicate by ELISA.  ELISA kit was obtained 
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from R&D Systems (Minneapolis, MN), and performed according to the manufacturer’s 
recommendation. 
2.5.3	   Retroviral	  integration	  
Retroviral integration was performed using retrovirus packaging system from Clontech 
(Mountain View, CA) according to manufacturer’s recommendation.  Briefly, selected 
gene switches were cloned into pLNCX2 retroviral vector.  The retroviral vectors were 
co-transformed together with pVSV-G envelope vector into the GP2-293 packaging cell 
line to produce retrovirus.  Supernatant containing retrovirus was collected after 2 days 
and used to infect HEK293 cells.  One day after infection, HEK293 cells were put under 
1000 µg/mL G418 selection.  The resistant cells were gathered after 2 weeks of selection 
and subsequently used for characterization studies. 
2.5.4	   Curve	  fitting	  
Curve fitting was performed using OriginPro 8.6.  The clonal ligand titration curve was 
fitted to the Hill equation, ! = !"# + !"# −!"# ∗ !
!
!!!!!
 where n is the Hill 
coefficient and k is the Km.  The heterogeneous population ligand titration curve was 
fitted using a weighted sum of 8 Hill equations. ! = !
!!!
[!! ∗ ! !"#,!"#,!, !! ]! , 
where f is a Hill equation with min = 0, max = 5000, n = 2.3, ki = [3.3x10-8, 1x10-7, 
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Chapter	  3:	  Coordinated	  induction	  of	  multi-­‐gene	  pathways	  in	  
Saccharomyces	  cerevisiae	  
3.1	   Introduction	  
Coordinated gene expression is an important tool in the biosynthesis of natural products, 
fine chemicals, and fuels (1-3). For example, the taxol biosynthetic pathway involves the 
synchronized action of at least 19 genes (4). In prokaryotes, genes involved in a 
biosynthetic pathway are often grouped together into an operon and are transcribed as a 
polycistronic mRNA under the regulation of a single promoter (5, 6). The operon 
structure makes it easy to regulate a large number of genes (7). In eukaryotes, especially 
filamentous fungi and even some plants, genes in the same pathway are also often 
grouped together into a gene cluster; but in contrast to that in prokaryotes, the genes are 
not under the same promoter, and may be subjected to independent regulation (8, 9). 
With rare exceptions, operons generally do not exist in eukaryotes (10).  
 
S. cerevisiae is an important industrial production host for heterologous pathways, and is 
generally suited for expressing pathways from fungi and plants, especially those 
involving cytochrome P450s (1). Being a eukaryote, it does not recognize operons, and 
each gene in a pathway will need to have its own promoters. This requirement can make 
construction of multi-gene pathways cumbersome. Traditionally, genes in pathways are 
usually broken up into multiple plasmids – at times only one gene on a plasmid (11), or 
two genes under a divergent promoter (12). In either format, the construction of a long 
pathway will require many plasmids and correspondingly many selection markers. 
Thanks to the recently developed large scale cloning methods, such as SLIC (13), Golden 
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Gate (14), Gibson (15), and DNA Assembler (16), large concatenations of promoters and 
genes can now be routinely made. However, large pathways constructed thus far are 
driven by constitutive promoters, because with the exception of Golden Gate, most of the 
assembly methods are homology dependent (17, 18), and non-homologous inducible 
promoters that respond to the same inducer are limited. Furthermore, it is commonly 
believed that due to the active homologous recombination machinery in yeast, 
homologous promoters should be avoided even if they do not interfere with DNA 
assembly (1).  
 
GAL inducible promoters are commonly used for controlling gene expression in yeast 
(19). However, due to the high cost of the inducer, galactose, its use in industrial 
production is limited (20). To circumvent this problem, we have employed an estrogen 
receptor based gene switch to activate GAL promoters. Because of its nanomolar 
sensitivity, only 200 µmol 17β-estradiol is needed to fully induce a 20,000L reactor, at a 
cost of roughly $1.20 (Sigma Aldrich catalog 2012). 
 
In this chapter, we present a system of constructing and activating multi-gene pathways 
in S. cerevisiae. The system consists of three parts: (a) a collection of inducible 
promoters, (b) an estradiol inducible yeast strain, and (c) a method of DNA assembly that 
allows for easy construction of inducible pathways in one step from PCR products. As a 
proof of concept, we assembled a five-gene zeaxanthin pathway, demonstrated the 
estradiol-dependent production of zeaxanthin, and characterized the pathway’s behaviour. 
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3.2	   Results	  
3.2.1	   Inducible	  promoter	  collection	  
The availability of natural GAL responsive promoters is limited to the genes involved in 
galactose utilization. To address this limitation, we cloned the GAL1, GAL2, and GAL10 
promoters into a GFP reporter and induced the GFP expression using Gal-P65, a 
constitutive gene switch made from the fusion between the GAL4 DNA binding domain 
and the P65 activation domain. As shown in Figure 3.1a, the natural GAL promoters 
exhibited tight regulation – the uninduced fluorescence level was indistinguishable from 
the background fluorescence. 
 
Figure 3.1 The behaviour of GAL inducible promoters, monitored via GFP expression and induced using 
Gal-P65. The GFP channel histograms obtained from flow cytometry are shown. Black indicates uninduced 
sample and red indicates induced sample. The sample identity and the percentage of positives are shown 
within each histogram. (a) The behaviour of natural GAL inducible promoters cloned from S. cerevisiae. 
(b) The behaviour of synthetic GAL inducible promoters, which were generated by fusing the synthetic 
UAS sequences with the TATA box of the GAL1 promoter. (c) Similar to (b), but fused with the TATA 
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To expand the dynamic range of the promoter collection, two sets of synthetic GAL 
responsive promoters were created. DNA fragments containing a varying number of 
consensus Upstream Activation Sequences (UAS) were joined to the TATA region of 
GAL1 and GAL2, creating the SYN1 and SYN2 collections of promoters respectively. 
As shown in Figure 3.1b and 3.1c, the induction strength of the promoter can be reduced 
by decreasing the number of UAS. In contrast to the tightly regulated GAL1 promoter, 
the SYN1 collection of promoters had noticeably higher basal levels. The SYN2 
collection of promoters did not suffer from increased basal level, and was generally 
weaker than the natural promoters. With the natural promoters and the SYN2 collection 
of promoters, induction strength across a wide dynamic range can be selected while the 
pathway of interest is maintained in tight control.  Further work on the engineering of 
GAL inducible promoters have recently been described by Blazeck et al. (25), which 
provided an even wider range of GAL inducible promoters to choose from. 
3.2.2	   Gene	  switch	  engineering	  and	  strain	  development	  
Domain Selection and Permutation. To identify the optimum configuration for the gene 
switch, we tested different orders of functional domains and different activation domains. 
The gene switches were co-transformed with PGAL10-GFP and tested for their inducibility 
using 100 nM estradiol. As shown in Figure 3.2a, P65-Gal-ER (6GE) had the best 
compromise between induction level and basal expression level, and was selected for the 
development of a series of estradiol-inducible yeast strains.  
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Figure 3.2 (a) Gene switch activity 
monitored via GFP expression, and 
measured using flow cytometry. GFP 
expression levels are represented by the 
arithmetic means of GFP fluorescence 
(arbitrary unit). The mean of negative 
control has been subtracted from that of 
the samples. Blue columns represent 
uninduced samples, and red columns 
represent induced samples. Values are the 
average of two independent samples and 
error bar indicates the standard error. 
Labels: CTR is negative control with 
empty plasmids, and Y2H is a yeast two 
hybrid system positive control from (29). 
GE, EG, AGE, AEG, 6GE, and 6EG are 
different combinations and permutations of 
Gal4 DBD(G), ER LBD(E), P65(6), and 
Gal4 AD(A) ordered from the N-terminus 
of the resulting gene switch protein. (b) 
Inducibility of the YZE strains monitored 
via GFP expression. The GFP channel 
histograms are shown. Black indicates 
negative control without gene switch, blue 
indicates uninduced sample, and red 
indicates induced sample. 
 
Estradiol-Inducible YZE Strains. After identifying the best gene switch configuration, we 
moved on to integrate the gene switch into YM954 so as to create a more convenient 
induction system as well as to reduce the number of plasmids required. The gene switch 
was integrated into the Lys2 locus without the use of antibiotic selection, thus leaving the 
most common auxotrophic markers intact and allowing the use of antibiotics for further 
genome engineering. Since the gene switch protein is not catalytically involved in the 
production of any desired compound, its over-expression will likely be detrimental to 
production. By placing the gene switch behind promoters of different strengths, the gene 
switch expression level will be varied in the different strains. Gene switch expressions in 
YZE-19, YZE-55, YZE-100, and YZE-149 are driven by the ENO promoter and its 




















































































ENO promoter. The expression in YZE-PA is driven by the ADH1 promoter. The 
functionality of these strains was confirmed by observing fluorescence from the induction 
of PGAL10-GFP upon estradiol addition. The flow cytometry GFP channel histograms 
from the strains were shown in Figure 3.2b. The mean fluorescence value shifted 
towards the right at higher promoter strengths. YZE-PA was not shown, but its histogram 
was indistinguishable from that of YZE-55.  
3.2.3	   Golden	  Gate	  pathway	  assembly	  
Pathway Assembly. Due to the limited availability of optimal inducible promoters, we 
designed the pathway assembly system based on the Golden Gate cloning method so that 
a single good inducible promoter can be re-used to control multiple genes if necessary. 
Details of Golden Gate cloning have been described by Carola et al. (14). Briefly, each 
fragment in the assembly is flanked by Type IIs restriction sites, e.g. BsaI, which cleaves 
the DNA away from its recognition sequence, leaving a user-defined 4 bp overhang. By 
judiciously choosing unique 4 bp overhangs, these fragments can be ligated together in a 
specific order to form the pathway. Because the restriction sites are lost when the correct 




Figure 3.3 (a) The inducible pathway assembly scheme. The T-P plasmids have BsaI-excisable terminator 
and promoter fragments, and the receiver plasmid has BsaI-excisable LacZα marker for blue-white 
screening. The toolbox plasmids together with the PCR products of the pathway genes can be used to 
assemble an inducible pathway in a Golden Gate one pot reaction. BsaI sites are in light blue, Kan is the 
kanamycin resistance gene, Spe is the spectinomycin resistance gene. (b) A schematic of the assembled 
inducible zeaxanthin pathway. All 4 intergenic T-P fragments are identical except for the 4bp overhang 
region. 
 
To allow for modular assembly of pathways, we constructed a toolbox that contains 
plasmids carrying the intergenic terminator-promoters and a receiver plasmid that has the 
first promoter and the last terminator. The assembly scheme is shown in Figure 3.3a. For 
proof of concept, these plasmids were put together with the PCR products of the 
zeaxanthin pathway genes (Crt E, B, I, Y, and Z), and an inducible zeaxanthin pathway 
was constructed in a one-step Golden Gate reaction. For this pathway, TPGI1-PGAL2 was 
selected for all intergenic terminator-promoters, PGAL2 was selected as the first promoter 
and TADH1 was selected as the last terminator (Figure 3.3b and Supplementary Figure 
B.1). As all five genes are under the same promoter, it allows for easier characterization 
of the inducible pathway. The assembly efficiency for the five-gene pathway was about 
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also constructed at a similar efficiency. When the assembled pathway was co-transformed 
with a plasmid carrying the P65-Gal-ER gene switch, the inducible expression of 
zeaxanthin occurred only in the presence of estradiol (Figure 3.4).  
 
Figure 3.4 (a) HPLC trace showing the inducible production of zeaxanthin. (b) Zeaxanthin production in 
different YZE hosts. Blue columns represent data from the first 24-hour samples. At the end of the 24-hour 
period, cells were re-inoculated into fresh media for another 24-hour. Red columns represent data from the 
second 24-hour samples. The values represent the average of 4 independent samples, and the error bar 
represents the standard error. 
 
Plasmid Stability. The intergenic T-P regions are approximately 800 bp long, and since 
TPGI1-PGAL2 was used for all T-P positions, the resulting plasmid contained four 800 bp 
direct repeats. It is commonly believed that plasmids with repetitive sequences are 
unstable in S. cerevisiae due to the presence of a highly active homologous 
recombination machinery (1, 21). We therefore performed a test of plasmid stability to 
see if the pathway will remain intact over multiple generations of propagations. 
 
Since the complete zeaxanthin pathway produces a yellow compound (and thus yellow 









































monitoring the number of white versus yellow colonies over continuous culture. The 
above zeaxanthin pathway was separately transformed into YZE-55 and YZE-PA, then 
plated onto selective plates. The initial colonies were collected, diluted, and re-plated 
with estradiol. The number of yellow and white colonies in this first re-plate was labelled 
as day 0 in Table 3.1. A yellow colony was then picked for uninduced continuous culture, 
diluting daily at 1/100, and an aliquot of the culture was plated with estradiol every two 
days (Supplementary Figure B.2). As shown in Figure 3.5, there was no significant 
increase in the number of white colonies after 8 days of continuous culture. With the 
exception of the day 0 re-plate, there were hardly any white colonies. A cell growing 
from the day 0 re-plate to day 8 saturated culture had gone through about 63 generations 
of divisions, more than enough to saturate a 20,000L batch reactor, and yet, only about 
0.5% of the cells had lost the pathway. This showed that the zeaxanthin pathway, despite 
multiple direct repeat sequences, could be stably propagated in S. cerevisiae.  
  
Figure 3.5 Assessment of plasmid stability. White colony is an indication that the yeast cell has lost at least 
part of the zeaxanthin pathway. The colony counts are the average of two independent experiments.  
 
 
Integrant Time Total Colony White Colony % White 
Day 0 60 12 20.00 
Day 2 243.5 0.5 0.21 
YZE-55 Day 4 195 1 0.51 
Day 6 360 1 0.28 
Day 8 267.5 1.5 0.56 
Day 0 110 39 35.45 
Day 2 295 1.5 0.51 
YZE-PA Day 4 195.5 0.5 0.26 
Day 6 404 2 0.50 
 Day 8 267 1 0.37 
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3.2.4	   Inducible	  pathway	  characterization	  
Protein Level Induction. While the promoters were characterized individually before the 
pathway assembly, putting multiple promoters together in the same plasmid may result in 
position dependency. Therefore, we sought to investigate whether the protein induction 
levels depend on where the gene is situated within the long concatenation of gene 
cassettes. Using the same toolbox plasmids as above, five more pathways were 
assembled, each with a different zeaxanthin pathway gene replaced with the GFP gene. 
The GFP gene in each of the five plasmids is thus under the control of the PGAL2 
promoter. Assuming that neighbouring structural genes do not interfere with promoter 
activity, any difference in induction level can be attributed to positional effect. As shown 
in Figure 3.6a, GFP at all five positions was estradiol inducible. The basal level 
expressions were indistinguishable from background fluorescence. The protein induction 
level appeared to dip at the 3rd and 4th position, but the expression level at all five 
positions varied by no more than two-fold. This showed that the genes at all five 
positions can be effectively regulated, even though the exact induction strength has some 
position dependency. 
 
mRNA Level Induction. Next, we investigated whether all five pathway genes can be 
induced simultaneously. Because the proteins were not tagged, we instead measured the 
mRNA level induction of the zeaxanthin pathway genes. As shown in Figure 3.6b, all 
five zeaxanthin pathway genes can be induced, and the trend in relative induction 
strength is the same as what we have observed from the GFP fluorescence measurement. 
This gave further evidence of the positional dependency of promoter strength. As mRNA 
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and protein abundance are not linearly correlated, a big change in mRNA level does not 
correspond to a big change in protein expression level, only the trend is consistent. 
Interestingly, when mRNA induction ratio and protein abundance as reported by GFP 
fluorescence are plotted against each other, a power-law trend emerged (Supplementary 
Figure B.3) – which coincides with the trend observed by Beyer et al. in their genome 
scale study of transcription-translation relationships in S. cerevisiae (22).  
 
Figure 3.6 (a) Protein level induction at the different positions using EGFP as the reporter. The genes 
along the pathway are arranged from 5’ to 3’ in the order Crt E-B-I-Y-Z. Zea is the negative control with 
the 5-gene inducible zeaxanthin pathway without any EGFP gene in it. E, B, I, Y, Z:EGFP have their 
respective zeaxanthin pathway gene replaced by EGFP. The uninduced EGFP-replaced pathways have 
identical basal expression levels, and they have been collapsed under crt:EGFP. The values represent the 
average of 4 independent samples, and the error bar represents the standard error. (b) mRNA level 
induction at the different positions as measured by quantitative RT-PCR. The value represents the average 
of 2 independent samples, and the error bar represents the standard error. (c) Production time course that 
benchmarks the inducible pathway in two different YZE strains to a constitutive pathway in YM954. The 
values represent the average of 3 independent samples, and the error bar represents standard error. (d) 
Ligand titration curve of the zeaxanthin production against the estradiol concentration. The values represent 

































































































Inducible Strain Comparison. Production of zeaxanthin was compared in the five YZE 
strains that differed in their promoters driving the gene switch expression. The inducible 
zeaxanthin pathway was transformed into the five strains and tested for their zeaxanthin 
production at 24 and 48 hours after induction. After sampling at 24h, the culture was re-
inoculated 1/100 into fresh media. As shown in Figure 3.4b, high gene switch promoter 
strengths, e.g. YZE-100 and YZE-149, are bad for production. YZE-19, 55, and YZE-PA 
showed similar production level at 24h but YZE-PA’s production decreased after re-
inoculation. YZE-19 and YZE-PA were picked for further comparison. 
 
Production Time Curve. YZE-19 and YZE-PA, each harbouring an inducible pathway 
plasmid, were compared to YM954 harbouring a constitutive pathway. The constitutive 
pathway was obtained from a previous publication and used as a benchmark in our 
comparison (16). To make the result more comparable, the constitutive pathway was re-
cloned into pRS416K2 which is the backbone of the inducible pathway, and YZE’s 
parent strain, YM954, was used to host the pathway. As shown in Figure 3.6c, YZE-19 is 
the best producer. At 72h post induction, YZE-19 accumulated roughly twice the 
zeaxanthin compared to YZE-PA and about 50-fold more compared to the constitutive 
pathway. The measured concentration by HPLC was 1.5 µg/mL, which corresponds to 15 
ng/OD600 cells or about 75 µg/g dry cell weight. 
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Ligand Titration. To identify an optimal inducer concentration, we performed a ligand 
titration in YZE-19 and YZE-PA. The strains harbouring the inducible pathway were 
subjected to different estradiol concentration, and the zeaxanthin production was 
measured after 48h. In agreement with the time course experiment, YZE-19 is a better 
producer. As shown in Figure 3.6d, it is in fact more sensitive to estradiol than YZE-PA. 
Peak induction in YZE-19 can be obtained at 10-8 M estradiol.  
3.3	   Discussion	  
In this study, we have presented a system for the construction and regulation of multi-
gene pathways in S. cerevisiae. Genes of an entire pathway can be concatenated together, 
each driven by an inducible promoter, forming a transcriptional unit that can be regulated 
as a whole – similar to what can be achieved by a bacterial operon. By using inducible 
promoters of different strengths for different genes, it is possible to balance the flux 
through the pathway, which is the main challenge in metabolic engineering and synthetic 
biology (23). 
 
We currently have a set of six promoters that are tightly regulated, with induction 
strength that spans an 8-fold difference from the weakest to the strongest. More inducible 
promoters have recently been developed by Blazeck et al. (24), and can easily be 
incorporated into our pathway construction system. As indicated in Figure 3.6d, 
induction strength can depend on the gene switch’s expression level, and can therefore 
differ in the different YZE strains. When using promoter strength to tune pathway gene 
expressions, it is also possible to pick induction strength through varying the ligand 
concentration. However, ligand titration curves need to be obtained in the host strain to 
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find out what the induction level is at any given ligand concentration. Furthermore, in this 
non-saturation range, small differences in ligand concentration can cause large 
differences in induction strength, making it difficult to control the induction level. For the 
above reasons, we find that it is best to vary induction strength by varying maximum 
induction levels. 
 
Based on the results of gene switch configuration assessment, we integrated the best gene 
switch into the chromosome to create five inducible yeast strains differing in gene switch 
expression levels. When used in conjunction with the inducible pathways, no additional 
plasmid is necessary. As shown in Figure 3.4b, high gene switch expression can be 
detrimental to the production of the desired product. Due to high clonal variation in 
adaptation, when a pathway is transformed into any given strain and induced on a plate, 
colonies with different degrees of yellow colouration (indicating zeaxanthin production) 
will occur. We picked both light- and dark-yellow colonies, assayed their product, and 
confirmed that they were all producing zeaxanthin, just at different levels (data not 
shown). High producing colonies occur at a frequency of roughly 1 in 10, and the 
adaptation can be propagated. When comparing the zeaxanthin production level in the 
different strains, we selected the darkest yellow colonies from each plate. 
 
Using the Golden Gate assembly method and our plasmid toolbox, the 5-gene zeaxanthin 
pathway can be assembled from their PCR products in a single step. This corresponds to 
a simultaneous ligation of 10 fragments forming a 13.3 kb plasmid with an efficiency of 
16%. Similar efficiency was observed for the assembly of 2 zeaxanthin pathways and 5 
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GFP-replaced pathways. As the correct pathways could be picked from a reasonable 
number of colonies, no optimization was performed. For longer pathways, optimization 
of the Golden Gate reaction condition will probably be necessary, and should 
optimization fail, a two-stage hierarchical assembly can instead be used. In that case, the 
toolbox will be expanded to include two to three ampicillin-resistant intermediate 
plasmids. PCR products of the genes and the T-P fragments from T-P plasmids will first 
be assembled into the intermediate plasmids, up to 5 genes at a time. The intermediate 
plasmids will then be used as the substrate for a second Golden Gate reaction, which puts 
the intermediate assemblies together into the final receiver plasmid. If a target gene 
contains the BsaI restriction site, it is possible to PCR-amplify the gene in multiple 
segments, breaking and replacing each natural BsaI site through primers. These 
fragments can then be used in the 1-step Golden Gate assembly system as per normal. 
Another way to work around the restriction site is to use another Type IIs restriction 
enzyme that gives a 4 bp 5’ overhang for the problematic target gene, and break the 1-
step assembly to 2-step assembly involving first digesting and then ligating. 
 
The initial transformations of the assembled zeaxanthin pathway have a significant 
fraction of white colonies (Figure 3.5), but when a yellow colony is picked and 
propagated, only 0.5% white colony can be observed after 8 days of continuous 
cultivation, with no increase in the percentage of white colonies over the 8 days. This 
suggests that the plasmid may be less stable in E. coli such that the initial plasmid 
preparation contained a small portion of truncated recombined plasmids, and the 
proportion was magnified through the preferential transformation of smaller plasmids. 
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Interestingly, when the plasmid for yeast transformation was prepared in the Stbl3 strain 
instead of the TOP10 or DH5α strains, the fraction of white colonies decreased 
drastically. Since Stbl3 is a strain better suited for amplifying unstable plasmids, it gives 
further evidence for plasmid instability in E. coli. 
 
Ideally, promoter strength should be independent of its position in the pathway, but this 
was not the case, at least for the GAL2 promoter. We observed that the induction strength 
tended to dip towards to middle of the pathway, and this has been supported at both 
protein (Figure 3.6a) and mRNA (Figure 3.6b) levels. One possible cause of this 
observation could be the 1-D search mechanism of DNA binding proteins. DNA binding 
proteins look for their cognate sequences in many ways, and one of the major search 
mechanisms is by first binding non-specifically to DNA, then performing a 1-D search 
along the DNA (25-27). The promoters at the flanks have access to a large ring of non-
cognate DNA, i.e. the plasmid backbone, and the gene switch will therefore have a higher 
chance of finding these promoters. In contrast, the promoters in the middle will have a 
much smaller binding area, and will have to rely more on a 3-D diffusion mechanism. 
More experiments are needed to verify this explanation and come up with a way to 
predict the modification of induction strength due to positional effect. 
 
Despite some positional dependency of induction strength, the pathway is tightly 
regulated – with no measurable production in the absence of estradiol. To benchmark the 
induced production, we used a constitutive zeaxanthin pathway previously reported in 
literature (16). Under the condition of our production time curve experiment, the 
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inducible pathway resulted in about 50-fold higher production level than the constitutive 
pathway. In making the comparison, we note that the genes on the constitutive pathway 
have five different constitutive promoters. Since constitutive promoters can sometimes be 
repressed under certain culture conditions, we may have just picked a poor production 
condition for the constitutive pathway. While we have not demonstrated the superior 
production capacity of an inducible pathway due to the above reason, we have at least 
demonstrated the greater reliability and predictability of an inducible system. Indeed, in 
another previous previously reported zeaxanthin production using S. cerevisiae, the 
authors achieved a similar production level as our inducible pathway using a mixture of 
inducible and constitutive promoters (2, 28). 
 
We chose GAL4 DBD and its corresponding UAS in our study because the GAL4 DBD 
based induction system has been well characterized and it is commonly employed for 
inducible expression in yeast. There is, however, a drawback in the system – being a 
native yeast protein, there are multiple regulatory and interaction targets for GAL4 DBD 
and some of these interactions can lead to unexpected phenotypes. For example, the YZE 
strains will not flocculate when induced, but if un-induced, will flocculate when the 
carbon source is exhausted. This could be due to interactions of GAL4 with other cellular 
signalling pathways, with the overall effect of tricking the cell into acting as if there is 
still galactose around.  
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3.4	   Conclusions	  and	  outlook	  
With the tools introduced in this chapter, biosynthetic pathways can be easily refactored 
and studied in S. cerevisiae. More importantly, entire pathways can now be predictably 
and reliably induced using estradiol, a commonly available chemical. If desired, the ER 
LBD can also be engineered to generate new orthogonal ligand-receptor pairs, giving us 
the ability to regulate multiple pathways simultaneously and orthogonally (29-31). The 
ability to coordinate the expression of multiple genes in S. cerevisiae will be a useful 
addition to the toolbox of microbiologists, metabolic engineers, and synthetic biologists. 
3.5	   Materials	  and	  methods	  
3.5.1	   Strains,	  plasmids,	  media,	  reagents,	  and	  cell	  cultivation	  
TOP10 (F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 araD139 Δ(ara- 
leu) 7697 galU galK rpsL (StrR) endA1 nupG λ-) and Stbl3 (F- mcrB mrr hsdS20 (rB-, mB-
) recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20 (Str) xyl-5 λ- leu mtl-1r ) (Life 
Technologies, Carlsbad, CA) were used for routine plasmid cloning and amplification in 
E. coli. YM954 (MATa; ura3-52 his3-200 ade2-100 lys2-801 trp1-901 leu2-3,112 gal4-
542 gal80-538) (kindly provided by Florence Vignols and Stanley Fields) was used for 
yeast experiments. Yeast strains were cultivated in either synthetic dropout medium 
(0.17% Difco yeast nitrogen base without amino acids and ammonium sulfate, 0.5% 
ammonium sulfate, and 0.083% amino acid dropout mix) or YPA medium (1% yeast 
extract, 2% peptone, and 0.01% adenine hemisulfate) supplemented with 2% glucose as a 
carbon source. E. coli strains were cultured in Luria broth (LB; Fisher Scientific, 
Pittsburgh, PA, USA). 
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YZE-19 through 149 and YZE-PA were created in this study by integrating the P65-Gal-
ER (6GE) gene switch into YM954 at the LYS2 locus, and are lys2+. pLys2-
PENO19,55,100,149-6GE and pLys2-PADH1-6GE were linearized with DraIII and transformed 
into YM954 by chemical transformation as described elsewhere (32). Integrants were 
selected using SC-Lys plates and confirmed by PCR as well as functional assay.  
 
All restriction and DNA processing enzymes were obtained from New England Biolabs 
(Ipswich, MA) and all chemicals were obtained from Sigma Aldrich (St Louis, MO) 
unless otherwise specified. PCR reactions were carried out using Phusion DNA 
Polymerase (Dharmacon, Lafayette, CO) and primers from Integrated DNA Technologies 
(Coralville, IA). 
3.5.2	   Plasmid	  construction	  
The natural GAL promoters were PCR amplified directly from the genomic DNA of S. 
cerevisiae. The resulting PCR products were overlap extended with another PCR 
fragment encoding the green fluorescent protein (GFP) and the ADH1 terminator. The 
promoter-gene-terminator cassette was subsequently ligated into pRS416 centromeric 
vector (ATCC 87521) via BamHI and SacI to create pRS416-Gal1-GFP, pRS416-Gal2-
GFP, and pRS416-Gal10-GFP. The synthetic GAL UASes were synthesized from 
overlap extension of oligonucleotides. These were overlap extended with the TATA box 
region of Gal1 and Gal2 to create the SYN1 and SYN2 series of promoters respectively, 
and subsequently cloned into pRS416 to create pRS416-SYN1-GFP and pRS416-SYN2-
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GFP. Sequences of SYN1 and SYN2 promoter can be found in Supplementary Figure 
B.6. 
 
The gene switch constructs were generated by ligation of either a P65 or GAL4 activation 
domain (AD) with an estrogen receptor ligand binding domain (ER LBD) and a GAL4 
DNA binding domain (DBD). The P65 and ER LBD were PCR amplified from human 
genomic DNA whereas the GAL4 AD and DBD were amplified from S. cerevisiae 
genomic DNA. The fragments were cloned directly into pRS414-PMT, which is a 
pRS414 vector (ATCC 87519) modified to contain an ADH1 promoter and ADH1 
terminator interspaced by a multiple cloning site.  
 
The gene switch integration plasmids, pLys2-PENO19,55,100,149-6GE and pLys2-PADH1-6GE 
were created by ligating the promoter fragments (EcoRI, KpnI) and 6GE-TADH1 (KpnI, 
MluI) into pLys2 (EcoRI, MluI), which is pNEB193 (New England Biolabs, Ipswich, 
MA) with the LYS2 gene inserted into the AatII site. PENO19, 55, 100, 149 promoters were 
obtained by random mutagenesis of the wild type ENO promoter as described elsewhere 
(33).  
 
The T-P plasmids were constructed by the ligation of the PGI1 terminator (AflII, EcoRI) 
and the GAL2 promoter (EcoRI, XbaI) into pFUS_A (AflII, XbaI) with appropriate BsaI 
sites introduced at the two ends of the T-P cassette. pFUS_A is an E. coli plasmid with a 
spectinomycin resistance marker as described elsewhere (34). The PGI1 terminator was 
PCR amplified from pRS416-Zeax which is a constitutive zeaxanthin pathway as 
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described elsewhere (16), whereas the GAL2 promoter was PCR amplified from the 
above-described pRS416-Gal2-GFP. 
 
The Golden Gate receiver plasmid, containing the first promoter and the last terminator 
interspaced by a BsaI-flanked LacZα cassette, was constructed by the overlap extension 
of the GAL2 promoter (from pRS416-Gal2-GFP), LacZα cassette (from pFUS_A), and 
ADH1 terminator (from pRS416-Gal2-GFP). The overlap extended fragment was cloned 
into pRS416K2 via HindIII and NotI. pRS416K2 was modified from pRS416 by the 
removal of all BsaI sites, the LacZα remnant, the f1 origin, and by the replacement of 
AmpR with KanR.  
3.5.3	   Pathway	  assembly	  
The Golden Gate reaction for pathway assembly was carried out in 20 µL using 100 ng of 
receiver plasmid, 100 ng of each T-P plasmid, 10 ng/kb of the PCR gene fragments, 1 µL 
of BsaI-HF, and 1 µL High Concentration T4 DNA ligase, in 1X T4 ligase buffer. The 
reaction was thermocycled as follows: 37 ºC for 10 min, (37 ºC for 5 min, 16 ºC for 10 
min) repeated 10 times, 37 ºC for 10 min, 75 ºC for 5 min. The ligation product was 
transformed into TOP10 competent cells (Life Technologies, Carlsbad, CA) by heat-
shock, and white colonies on X-GAL/IPTG plates were screened for the correctly 
assembled pathway. Primer sequences used to obtain the PCR gene fragments are listed 
in Supplementary Figure B.4. 
3.5.4	   Measurement	  of	  GFP	  expression	  
GFP expression level was measured by flow cytometry using LSRII (BD Biosciences, 
Franklin Lakes, NJ). Single colonies were picked into liquid synthetic dropout media and 
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grown overnight with or without induction. Small aliquots of the cultures were then 
washed and resuspended in phosphate buffered saline for flow cytometry analysis. 
3.5.5	   Measurement	  of	  zeaxanthin	  production	  
Cells from 6 mL of S. cerevisiae dropout media culture were collected by centrifugation, 
resuspended in 1 M sorbitol, 10 mM Tris Buffer pH 7.4, 5 U/mL Zymolyase (Zymo 
Research, Irvine, CA), and incubated at 37 ºC for 45 min. Cells were then collected again 
by centrifugation and 600 µL methanol was used to extract the zeaxanthin directly. For 
quantification, 80 µL of methanol extract was loaded onto an Agilent ZORBAX SB-C18 
column and monitored at 450 nm on an Agilent 1100 series HPLC (Agilent 
Technologies, Palo Alto, CA). The pump program was 0.6 mL/min, 100% methanol for 
10 min. Elution was monitored at 450 nm with reference set at 360 nm. Authentic 
zeaxanthin from Sigma (St Louis, MO) was used as a standard. 
3.5.6	   RNA	  preparation	  and	  quantitative	  PCR	  
Yeast colonies were picked from synthetic dropout plates into 3 mL synthetic dropout 
medium and grown overnight at 30 °C with shaking at 250 RPM to saturation. 100 µL of 
overnight culture was then used to inoculate 3 mL of fresh media, and estradiol was 
added to the appropriate samples. After growing for 18 hours, cells from 0.5 mL of each 
culture were harvested by centrifugation. RNA was then isolated using the RNeasy Mini 
Kit (QIAGEN, Valencia, CA) according to the manufacturer’s protocol.  1 µg of the 
resulting total RNA was treated by 10 units of recombinant DNaseI (Takara Bio, Otsu, 
Shiga, Japan) in 20 µL for 40 minutes according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was then synthesized using the iScript cDNA Synthesis 
Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol and stored at -20 
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°C until use. Quantitative PCR primers were designed using the Primer3Plus software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) (Supplementary 
Figure B.5).  Reactions were performed using Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems, Austin, TX) according to the manufacturer’s 
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Chapter	  4:	  A	  high-­‐throughput	  TAL	  effector	  synthesis	  platform	  
4.1	   Introduction	  
Recombinant transcription activator-like effector (TALE) technology has become a 
versatile platform for genome editing (1-4) and genetic regulation (5-8). TALE proteins 
were first discovered in Xanthomonas, a genus of plant bacteria, and its DNA recognition 
code was solved in 2009 (9, 10). In the following years, intensive research efforts 
expanded the host range of TALE from plant to yeast, nematode, zebrafish, frog, cattle, 
human, and others (11). DNA recognition by TALE is carried out by the central repeat 
domain (CRD), which contains multiple repeats of a 33-35 amino acids (aa) motif. Each 
of the repeats recognizes a single DNA nucleotide, and the recognition specificity is 
determined by the highly variable aa at position 12 and 13, called the repeat-variable 
diresidue (RVD). Due to the modular nature of TALE and the one-to-one correspondence 
between RVD and DNA nucleotide, researchers can specify the DNA binding sequence 
of a TALE by assembling the appropriate repeats in a tandem array.  
 
A cost-effective, high-throughput TALE synthesis platform is needed to support the next 
stage of TALE technology development, i.e., to expand its use as a tool for the general 
research community and for large genome-scale engineering applications. Three general 
strategies have been used to address this challenge: solid-phase (12, 13), ligation-
independent cloning (LIC) (14), and Golden Gate (GG) (15, 16). While highly scalable, 
solid-phase platforms suffer from low inherent fidelity due to the lack of specific 
junctions for every fragment, and high reagent cost because fresh reagents need to be 
added at every elongation step. LIC and GG both exhibit high inherent fidelity, but the 
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strong antagonistic relationship between maximum number of fragments and assembly 
efficiency limits the number of fragment that can be assembled at high efficiency. In the 
LIC and GG high-throughput synthesis platforms reported so far, a maximum of 6 
fragments can be simultaneously assembled (16) (typically much fewer (14, 15)), beyond 
which the decrease in efficiency becomes untenable. Limited by the number of 
fragments, current high-throughput methods suffer from lower flexibility in the number 
of repeats a TALE can contain, and they also require higher multimer fragments to 
achieve a targeted number of repeats. Since the size of the substrate library scales 
exponentially (4n) with the number of repeats within a fragment and only linearly with 
the number of fragments, having high multimer fragments lead to large substrate library. 
 
Despite the multitude of assembly technologies, they suffer from a common downstream 
bottleneck – clonal isolation. In a typical TALE synthesis scheme, the assembled TALEs 
are transformed into E. coli for plasmid amplification. Due to the limited assembly 
efficiency, E. coli clones need to be isolated and screened before expression-ready 
TALEs can be obtained. The clonal isolation requirement adds significant time and cost 
to the overall synthesis scheme, and encumbers the application of the current 
technologies for large-scale synthesis. In genome-scale applications such as genetic 
screening or evolution through knock-out (TALEN) or gene activation/repression 
(transcription factor), thousands of TALEs will be needed. For such applications, the 
TALEs do not have to be absolutely pure, but they need to be pure enough to be highly 
functional, and most importantly, they have to be cheap. 
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Here, we introduce fairyTALE, a liquid-phase GG-based high-throughput TALE 
synthesis platform capable of transforming a desired target sequence into an expression-
ready plasmid in a single day, without the need for clonal isolation, at a material cost of 
just $5 per TALE. FairyTALE represents a significant improvement over current 
platforms in terms of efficiency, flexibility, cost, and speed. This new platform should 
greatly facilitate the expansion of the recombinant TALE technologies for genome-scale 
applications.   
4.2	   Results	  
4.2.1	   Design	  of	  the	  fairyTALE	  system	  
The fairyTALE system assembles TALE CRDs from a library of fragments, which are 
carried by their respective substrate plasmids, excisable through the type IIs restriction 
enzyme – BsaI. The fragments contain either a mono-repeat or a di-repeat in which two 
TALE repeats have been pre-assembled together. The substrate library is comprised of 
308 substrate plasmids, divided into 16 groups according to their positions in a CRD 
assembly. There are 13 groups that each have 20 plasmids – 16 di-repeats and 4 mono-
repeat plasmids (Figure 4.1a). The remaining 3 groups each contain only 16 di-repeat 
plasmids. Using a GG assembly scheme (17), the mono- and di-repeat fragments are 
excised from their respective substrate plasmids, spliced together in a predefined order, 
and ligated onto a receiver plasmid, forming a complete TALE in a single step. The 
receiver plasmids contain the last half repeat, and can also include the N- and C- terminus 
extension, as well as functional domains such as FokI or VP64 (Figure 4.1b). 
FairyTALE can utilize two assembly schemes to generate TALEs with varying numbers 
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of repeats. In the standard assembly scheme, one plasmid from each of the 13 groups is 
chosen according to the desired target sequence and used for assembly. By choosing 
either mono- or di-repeats at each position, the length of TALEs can be flexibly 
determined, and TALEs containing between 13.5 and 26.5 repeats can be constructed. In 
the extended assembly scheme, group 5 in the original 13 is expanded into 3 new groups 
– 5A, B, C – each with only di-repeat substrates (Supplementary Figure C.1). By using 
substrates from the 15 groups, TALEs containing up to 30.5 repeats can be constructed. 
 
Figure 4.1 (a) Within a typical group, there are 16 di- and 4 mono-repeat plasmids, covering all possible 
combinations of 2 or 1 RVD. Every group has a unique and defined position in the assembly. (b) A BsaI 
GG reaction assembles 13 substrate fragments in one step, in the process displaces the ccdB toxic gene. 
Assembly can be made into either an intermediate receiver or functional receiver. Sequence specificity is 
dictated by the choice of di- and mono-repeat from each group. (c) CRD assembled in an intermediate 
receiver can be transferred using an Esp3I GG reaction into multiple functional receivers. 
 
FairyTALE has incorporated the latest RVD usage – NI for adenine, NG for thymine, HD 
for cytosine, and NH for guanine (18). All 308 di- and mono-repeats have been generated 
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using a robotic liquid handling system from just 28 parts, and they can therefore be 
updated easily if necessary. Using codon redundancy, unique primer annealing regions 
have been incorporated into group 5 and group 9 substrate plasmids so that the final 
product can be fully sequenced.  
 
For maximum functionalization flexibility, the repeats are assembled into pLR 
intermediate receivers, which contain the last half-repeat as well as a flanking Esp3I site 
for high efficiency transfer of the assembled CRD (Figure 4.1c) to the functional 
receivers. This 2-step synthesis route is useful when multiple functionalizations, such as 
both activator and repressor, of the same CRD are desired. For maximum synthesis 
speed, assembly can be done via a 1-step synthesis route, where the repeats are assembled 
directly into functional receivers such as TALE nuclease (TALEN) plasmids. The 
TALEN plasmids used in this work, pYW-TN and pYW-LR-TN, contain a +207 aa N-
terminus extension, a +63 aa C-terminus extension, and a FokI cleavage domain(19). The 
C-terminus extension and FokI have been engineered for improved activity in yeast as 
well as in mammalian cells(20). All receivers have utilized the ccdB counter-selection 
cassette to eliminate background clones during transformation.  
 
The set of GG junctions used in fairyTALE have been selected for ligation efficiency, 
which can vary by as much as 30% among the different junction sets tested. All junctions 
tested are non-palindromic but differ in their GC contents. In general, we have chosen 
junction that have between 50% to 75% GC content. Given the surprising variability 
among the different sets, we attribute a large part of the exceptional efficiency exhibited 
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by fairyTALE to the specific collection of GG junctions. The exact sequences of these 
junctions can be found in Supplementary Figure C.2.  
4.2.2	   Assembly	  process	  
To ensure uniqueness in the human genome, a target length of at least 17 bp is required, 
assuming random sequence composition. However, the human genome is far from 
random, and contains numerous repetitive and low complexity regions. Furthermore, due 
to the mismatch tolerance of TALE (21), a longer target sequence will be necessary to 
ensure uniqueness. For most TALE applications, 26.5 repeats, recognizing a 27 bp target, 
should offer sufficient specificity. For TALEN applications, a heterodimer is required to 
make a cut, thus contributing to further stringency. Recent evidence also suggests that 
longer TALE may not offer better specificity because the specificity of TALE repeats 
appears to decrease towards the C-terminus end (21). We have therefore focused our 
development and characterization on the 13-fragment standard assembly scheme. For 
proof of concept, we selected 90 sites of 27 bp length from 12 different yeast promoters. 
The sites have been chosen purely based on their position from the transcriptional start 
site, with no regard to sequence composition nor any of the TALE design guidelines (4, 
22). 
 
A robotic liquid handling system performed the pipetting of substrate plasmids and 
receiver plasmids. After a one-pot GG reaction, the mixture was transformed into Z-
competent E. coli. One-third of each transformation was plated while the rest was 
transferred directly into LB+antibiotic liquid culture for polyclonal plasmid purification. 
After one day, the colonies on the plate were then picked for monoclonal plasmid 
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purification and assembly efficiency assessment. Using a standard curve, the apparent 
plasmid yield from the GG reaction can be estimated from the number of colonies on the 
plate. We defined specific yield as apparent yield divided by theoretical maximum yield, 
and it determines the transformation efficiency requirement in the later step. Details of 
specific yield estimation can be found in Supplementary Figure C.3.  
 
The performance of the standard assembly scheme was evaluated using both the 2-step 
and 1-step synthesis routes. For the 2-step route, the specific yield of the intermediate GG 
reaction was ~2%. Given a theoretical maximum yield of 50 ng, this corresponds to the 
production of ~1 ng circular plasmid, which is expected to give 1000 colonies at a 
transformation efficiency of just 1x106/µg. This allows us to use a low-cost and highly 
scalable transformation procedure such as Z-competent transformation.  
 
We randomly selected 64 colonies (3 colonies each from 16 different assembly reactions 
during large-scale synthesis and another 16 colonies during pilot trial) for monoclonal 
plasmid purification and analysis by agarose gel electrophoresis. All 64 clones showed 
the expected 5 kb supercoiled band (Figure 4.2a), corresponding to an efficiency of 
100% (64/64). More importantly, when the monoclonally purified plasmids were 
compared to the polyclonally purified plasmids, they were virtually indistinguishable. 
This allowed us to skip plating without compromising the resultant plasmid quality. We 
fully sequenced 24 of the polyclonal plasmids using two flanking and one internal primer. 
All the sequencing reactions gave clean reads, indicating that the polyclonal plasmids 
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were of good quality, and all showed the expected sequences. Sample sequencing traces 
from a polyclonal plasmid preparation can be found in Supplementary Figure C.4. 
 
Figure 4.2 42 clonal plasmids from 14 different assemblies are shown in the top three rows, and the 
corresponding polyclonal plasmids are shown in the bottom row. Incorrect assemblies were highlighted by 
red boxes. NEB supercoiled ladder is used for (a) and NEB 1kb ladder is used for (b-c). (a) Typical result 
of assembly into an intermediate receiver, correct assembly is ~5kb. (b) Typical result of a transfer into a 
functional receiver, digested with HindIII and StuI, correct assembly shows a 3.7kb band. (c) Typical result 
of a 1-step assembly into a functional receiver, also digested with HindIII and StuI. 
 
The transfer reaction was carried out in a one-pot GG reaction using the purified 
polyclonal plasmids as substrates and pYW-TN as the functional receiver. The specific 
yield of this step was ~23%, and the correct digestion pattern was observed in ~98% 
(54/55) of the monoclonal plasmids (Figure 4.2b). Initially, 3 colonies each from 16 
different assemblies were assessed, and 1 error was found. To ensure that the error was 
random, we assessed an additional 7 colonies from the plate containing the original error. 
The functionalized TALEs (in this case, TALENs) were once again purified from both 
monoclonal and polyclonal cultures, and the purity of the polyclonal plasmids were 
indistinguishable from that of monoclonal plasmids according to restriction digestion.  
 
For the 1-step synthesis route, substrate fragments were directly assembled into 
functional receivers such as pYW-LR-TN. This reaction scheme achieved a specific yield 



























plasmids were also indistinguishable from that of clonal plasmids in terms of digestion 
pattern (Figure 4.2c). All 20 direct assembly polyclonal plasmids we sequenced gave 
clean reads and showed the expected sequences. 
 
For the extended assembly scheme comprising a similar 15-fragment GG reaction, the 
specific yield was ~1.6%, the polyclonal plasmid appeared pure on agarose gel, and also 
generated clean sequencing reads. We sequenced 6 of the polyclonal 15-fragment 
assemblies, and they all showed the expected sequences. Since few TALE applications 
would require a 31 bp target sequence, no further characterization on the extended 
assembly scheme was performed. 
4.2.3	   Functional	  validation	  
To determine the fidelity of fairyTALE, we assessed the activity of the assembled TALE 
CRDs on their expected target sequences. The activity was assayed in Saccharomyces 
cerevisiae using a GFP plasmid TALEN reporter system(20). As shown in Figure 4.3a, 
two overlapping halves of the GFP gene were separated by a heterodimeric TALEN 
binding site containing in-frame stop codons. When a cut was made, the GFP reading 
frame could be restored by homologous recombination. To obtain a good indicator of 
CRD DNA binding activity, we kept one monomer of the TALEN heterodimer constant, 
so that the GFP signal reflected the relative DNA binding activity of the variant 
monomer. The fairyTALE-generated half-TALENs were paired with a previously 
generated Xa10 half-TALEN(20) in this functional assay, and the GFP signal was 
measured using flow cytometry. 
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Figure 4.3 (a) The GFP TALEN reporter. The Xa10 binding site is constant, and the TALEN binding site 
is unique for every TALEN we tested. Light green portion represents the GFP homology region. When a 
cut is made, homologous recombination restores the disrupted GFP. GFP fluorescence is therefore an 
indicator of TALEN activity. (b) The TALEN activity of 16 different TALENs, each obtained through 
three different synthesis routes – direct synthesis polyclonal plasmid (polyclonal), direct synthesis clonal 
plasmid after colony picking (clonal), and 2-step synthesis polyclonal plasmid (transfer). GFP fluorescence 
has been normalized by the activity of I-CreI positive control. Reporter alone control and uninduced 
TALEN control showed no detectable activity. 
 
Using the GFP TALEN reporter system, we compared the TALEN activities of 1-step 
assembly polyclonal plasmids, 1-step assembly monoclonal plasmids after colony 
picking, and 2-step assembly polyclonal plasmids after transfer. We randomly chose 16 
different TALENs for this comparison, and there were no significant differences in 
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polyclonal plasmids not only digested and sequenced like clonal plasmids, but also 
functioned like clonal plasmids. 
 
Overall, when all the TALENs were assessed, ~96% (87/90) of the TALENs tested 
showed nuclease activity. A TALEN was considered active if it showed at least half the 
activity of the I-CreI positive control. We sequenced the three inactive TALENs, and the 
results showed that all had been assembled correctly. The lack of activity therefore 
suggested a lack of binding rather than assembly error. The level of activity varied 
greatly among the TALENs, ranging from ~0.1 to ~20 normalized fluorescence. Under 
the TALEN scaffold used in our tests, the preceding T appears to be non-essential for 
TALEN activity. This property is likely an attribute of the scaffold as suggested in 
previous work(19), and may not generalizable to all TALEN scaffolds currently used by 
the scientific community. Target sequences with long stretches of A, T and very few C 
appeared to function poorly, in agreement with previous observations (22). However, 
having a high number of strong RVD alone is also not sufficient to guarantee high 
activity. There appears to be as yet undetermined factors that affect TALE binding 
efficiency. However, we have too few inactive TALEs among our targets to discern any 
rule, and no obvious trends are observed among the active TALEs. Activity data of the 90 
TALENs can be found in Supplementary Figure C.5. 
 
4.3	   Discussion	  
There are few performance indicators available to assess and compare current high-
throughput synthesis platforms. We characterized our platform using three parameters 
 81 
that we consider to be key for evaluating the performance of high-throughput synthesis 
systems. First – specific yield, which represents the efficiency of mass transfer during the 
assembly reaction, and is estimated by actual plasmid yield divided by theoretical 
maximum yield. High specific yield will allow the use of a smaller amount of starting 
material and/or less efficient competent cells. Second – efficiency, which represents the 
effectiveness and accuracy of the assembly reaction, and is estimated by the fraction of 
correct clones out of all clones. High efficiency will allow the picking of fewer colonies 
to get a correct clone. Third – cost, which measures the monetary and time input 
necessary to produce expression-ready plasmids. Monetary cost should include all 
reagents and consumables. Time cost should include the entire assembly process from a 
desired sequence to a final expression-ready plasmid.  
 
Analogous to the $1000 genome threshold in genome sequencing(23), there are 
performance thresholds in high-throughput TALE synthesis that will allow substantial 
non-linear throughput improvement. The most significant contributor to time and cost of 
a synthesis process is clonal isolation and the subsequent screening. Extremely high 
assembly efficiency can negate the need for clonal isolation and allow direct polyclonal 
plasmid purification. There is no clear guideline for deciding what the minimum 
efficiency needs to be, but if the polyclonal products digest, sequence, and function just 
like their clonal counterparts, the efficiency is most likely sufficient. Among all synthesis 
platforms published thus far, only Schmid-Burgk et al. produced usable polyclonal 
plasmids at about 85% purity (14). Limiting dilution can be used in place of plating to 
obtain a clonal culture, but it increases the total process cost due to duplicated culture and 
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plasmid purification. Likewise, the efficiency of all other high-throughput synthesis 
systems, including Kim et al.’s tri-mer Golden Gate assembly platform(16), is around 
85%, and clonal isolation needs to be performed before transformation. In comparison, 
fairyTALE has an efficiency of ~98%, achieved by using a 13-fragment GG reaction, 
more than twice as many fragments as previous platforms. The ability to ligate more 
fragments reduces the size of the substrate library and increases the maximum length of 
the generated TALEs. Moreover, we have shown that, at ~98% efficiency, the direct 
polyclonal plasmids obtained using fairyTALE are experimentally equivalent to 
monoclonal plasmids in all measures. 
 
Although clonal isolation and individual confirmation is still the preferred practice for 
low-throughput dedicated applications where a few TALEs are used to target a few 
targets, it is prohibitively expensive for high-throughput applications where thousands of 
TALEs are used to target thousands of targets. Furthermore, in applications such as 
genetic screening or engineering using a library of TALENs or TALE transcription 
factors, absolute purity becomes less important.  
 
High efficiency bacterial transformation can potentially add significant cost to the 
process. Therefore, the ability to use low efficiency competent cells, which are easier and 
cheaper to produce and transform, is important. The typical transformation efficiency of 
home-made Z-competent Top10 is between 105 and 106/µg pUC19, and a specific yield 
threshold that will allow the use of this low-cost transformation method is around 0.5%. 
FairyTALE meets this threshold and can consistently produce hundreds of transformants 
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in 13-insert GG reactions. Specific yield has been an under-appreciated performance 
parameter, and no synthesis method published so far has reported it. 
 
The overall cost of synthesis is of paramount importance when it comes to high-
throughput synthesis – an extra dollar spent per reaction can very quickly scale to tens of 
thousands of dollars. At every step of the synthesis process, conscious design 
considerations are required to minimize the cost. At $5 per TALE and one-day synthesis 
speed, fairyTALE can potentially make TALE as accessible as oligonucleotides are today 
(Breakdown of cost estimate can be found in Supplementary Figure C.6). The typical 












Figure 4.4 A typical synthesis timeline: 
fairyTALE can transform desired DNA 
binding sequences to expression-ready 
TALE plasmids in one day. 
Lyophilization is necessary in this case 
because large volume addition is required 




The low cost high-throughput synthesis also makes possible a wide range of genome 
engineering applications that require a large number of TALEs. For example, as 
suggested by Kim et al. (16), a collection of human knockout cell lines covering every 
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non-essential gene is highly desirable. Without the need for clonal isolation, fairyTALE 
can very quickly generate all the necessary TALENs to carry out the knockout. In 
combination with the SunnyTALEN scaffold, which has improved activity over existing 
TALENs, knockout efficiency can be increased, therefore reduces the amount of 
downstream work for cell line development. Knockout collection of many other cell 
types can be similarly developed. 
 
One application where extremely high synthesis efficiency is critical is library synthesis; 
in which tens of thousands of TALEs are individually assembled and then combined into 
a library without getting individually verified. The library can be used for genome 
evolution and/or genetic screening to identify genes of interest associated with certain 
phenotypes. If all the steps after the initial GG assembly reaction, e.g. transformation and 
plasmid preparation, can be done as a library, the synthesis cost per TALE can be 
reduced to just $2 per TALE. However, because no clonal isolation can be done in such a 
synthesis scheme, extremely high synthesis efficiency becomes a requirement.  
 
Lastly, in Figure 4.5, we attempt to compare and summarize all TALE synthesis 
platforms published to date. With superior efficiency and lower cost, fairyTALE has the 

































Date 1/19/11 3/31/11 4/14/11 5/19/11 4/8/12 6/26/12 12/16/12 2/7/13 2/17/13 - 
# of Parts 72 32 50 72 376 12 64 3072 832 424 308 
Efficiency NR NR NR NR NR 85% 85% 82% NR 82% >98% 










































Figure 4.5 A comparison of existing TALE synthesis platform with a timeline of development. Specific 
yield and material cost are not tabulated because no other work has reported them. Synthesis platforms 
from the time of Reyon et al. onwards are generally considered high-throughput. NR: Not Reported. 
 
4.4	   Conclusions	  and	  outlook	  
Now that we have the ability to synthesize a large number of DBD, we can start to 
explore the use of TALEs for genome engineering. For a proof of concept, we can use S. 
cerevisiae as our model organism. TALE activators targeting every S. cerevisiae gene can 
be synthesized and transformed as a library. This yeast library is then subjected to various 
stresses such as thermal tolerance and chemical tolerance. Members of the library that 
show improved stress tolerance, as well as the TALEs that they carry, will be isolated and 
characterized. From the target sequences of the TALEs isolated, we can identify the list 
of genes that is involved in the selected phenotype. 
4.5	   Materials	  and	  methods	  
4.5.1	   Substrate	  plasmid	  construction	  
Each substrate plasmid can be assembled from four parts – front, RVD1, RVD2, back – 
with 5 junctions in total. The front and back are sequences that bridge adjacent di-repeats; 
they, as well as their distal junctions, are constant within each group of substrate 
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plasmids. We first constructed 16 plasmids, pFB1 through 13 and pFB5A through C, that 
contain the front and back of each group with an Esp3I-excisable cassette between them. 
The set of three proximal junctions around the RVDs are constant in all substrate 
plasmids, and a Type IIs ligation reaction is used to insert RVD1 and RVD2 between the 
front and back fragment to create di-repeats. In a similar manner, mono-repeats are 
generated by inserting RVDM, which has a single RVD with junctions compatible with 
the front and back fragments. All 308 substrate plasmids were generated using a robotic 
liquid handling system from 16 pFB plasmids, 4 RVD1 fragments, 4 RVD2 fragments, 
and 4 RVDM fragments. All RVD fragments are short, and can be generated by direct 
synthesis, thus allowing easy future upgrade or expansion. More details can be found in 
Supplementary Figure C.7. 
4.5.2	   Receiver	  plasmid	  construction	  
A type IIs ligation strategy was used to construct pLRX-ccdB, a precursor of the pLR 
series of intermediate receivers, from three parts – two ccdB fragments and a LRX 
fragment. The ccdB cassette without chloramphenicol resistance was PCR amplified in 
two fragments from a Gateway destination vector (Life Technologies, Carlsbad, CA), 
removing the internal BsaI site within ccdB. The LRX fragment, which contains a last 
repeat precursor, was generated by direct synthesis (Integrated DNA Technologies, 
Coralville, IA). The series of 4 pLR receivers were generated from pLRX-ccdB by XcmI 
linearization followed by In-Fusion (Clontech, Mountain View, CA) with the appropriate 
RVD-containing PCR fragments. pYW-TN and pYW-LR-TN contain a Trp1 marker for 
yeast selection, a Gal2 promoter for inducible expression, a +207 aa N-terminus 
extension with NLS added for improved activity in yeast and FLAG tag added for easy 
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expression analysis, an engineered +63 aa C-terminus extension and FokI cleavage 
domain for improved cleavage activity in yeast as well as in human. In pYW-TN, the 
ccdB cassette is flanked by Esp3I, and is designed to receive a CRD assembly from pLR. 
In pYW-LR-TN, the ccdB cassette is flanked by BsaI, and is generated by a cassette 
exchange between pYW-TN and pLR using Esp3I. pYW-LR-TN will allow direct 
assembly of substrate plasmids. All ccdB-containing plasmids were propagated in E. coli 
DB3.1. More details can be found in Supplementary Figure C.8. 
4.5.3	   13-­‐	  and	  15-­‐piece	  Golden	  Gate	  assembly	  
All substrate plasmids and receiver plasmids were normalized to equal-concentration, 
diluted with water, and stored in 96-well storage plates. Using a liquid handling robot 
(CyBio AG, Germany), interfaced with a custom command script, the appropriate 
substrate and receiver plasmids were pipetted into a 96-well PCR plate. Due to the 
pipetting precision of our robotic system, 5 µL of each plasmid were added for 
reproducible transfer, thus resulting in a final volume of >65 µL. The plasmid mixtures 
were first lyophilized before Golden Gate reaction. 25 ng of each substrate plasmid, 25 
ng pLR or 50 ng pYW, were used in a 10 µL Golden Gate reaction – 0.5 µL BsaI-HF, 0.5 
µL T4 ligase (New England Biolabs, Ipswich, MA) in 1× T4 ligase buffer. The reaction 
was carried out in a thermocycler using the following program: 37 ºC for 5 min, 37 ºC for 
5 min, 16 ºC for 10 min, repeat 2-3 for 20 cycles, 16 ºC for 20 min, 37 ºC for 30 min, 75 
ºC for 6 min, 4 ºC hold. After the thermocycling, 0.25 µL of plasmid-safe nuclease 
(Epicenter), and 0.5 µL of 25 mM ATP was added to the reaction, and incubated further 
at 37 ºC for 15 min. 4 µL of the resultant reaction was transformed into either Z-
competent (Zymo Research, Irvine, CA) Top10 (Life Technologies) or Stellar (Clontech). 
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Competent cells with greater than 5×105/µg pUC19 transformation efficiency would 
suffice. The Golden Gate reaction condition reported here has been optimized for high 
specific yield and high specificity. More information on the reaction optimization can be 
found in Supplementary Figure C.9. 
4.5.4	   Golden	  Gate	  transfer	  reaction	  
50 ng of pLR assembly and 50 ng of pYW-TN were used in a 10 µL Golden Gate 
transfer reaction – 0.5 µL Esp3I (Thermo Scientific, Waltham, MA) and 0.5 µL T4 ligase 
in 1× T4 ligase buffer. The reaction is carried out in a thermocycler using a similar 
program as above, but with only 10 cycles. 4 µL of the resultant reaction was transformed 
into Z-competent Stellar.  
4.5.5	   Assembly	  efficiency	  determination	  
The initial E. coli transformations were each split into two parts, 1/3 of it was plated onto 
LB+antibiotic plate for colony picking and monoclonal DNA isolation; 2/3 of it was 
directly inoculated into 5mL LB+antibiotic liquid culture for polyclonal DNA isolation. 
The plasmids isolated from the monoclonal DNA preps and that from polyclonal DNA 
preps were analyzed by agarose electrophoresis. A more detailed on this procedure can be 
found in Supplementary Figure C.10. 
4.5.6	   GFP	  TALEN	  reporter	  assay	  
The reporter assay was carried out in YZE-19, an estrogen-inducible yeast strain(26), 
using a 3-plasmid system with a disrupted GFP TALEN reporter, a Xa10 TALEN(19), 
and a fairyTALE-generated TALEN. The disrupted GFP reporter precursor, 416K2-GFP-
GG, was constructed by PCR and regular ligation. The disruption cassette has a 5’-Xa10 
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binding site and a BsaI-flanking 3’-ICreI binding site. 90 TALEN reporters were 
generated by exchanging the 3’-ICreI site with 90 chemically synthesized TALEN 
binding sites. The sequences of the target sites can be found in Supplementary Figure 
C.11. The Xa10 plasmid was first transformed into YZE-19; subsequently, a fairyTALE 
TALEN plasmid and its corresponding GFP TALEN reporter plasmid were co-
transformed into the same strain. Transformants were allowed to expand in SC-LWU 
(glucose) media for 2 days with daily one-tenth passage. TALEN expression was induced 
on the third day using 0.1 µM 17β-estradiol, and GFP expression was assayed using flow 
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Chapter	  5:	  Development	  of	  a	  single-­‐plasmid	  TALEN	  system	  
5.1	   Introduction	  
TAL Effector Nuclease (TALEN) is a class of engineered DNA nuclease that allows 
user-designed targeting sequence (1, 2). Since its inception as a customizable gene-
targeting tool in 2011 (3), it has been successfully used to carry out site-specific genome 
modifications in a plethora of organisms (4). Due to its relatively long recognition 
sequence (usually >30bp), a TALEN exhibits minimal off-target effects, and is therefore 
the preferred tool when targeting specificity is important (5, 6). Together with Zinc 
Finger Nuclease, TALEN was chosen as Nature Method of the Year 2011.  
 
A TALEN consists of a heterodimer of two separate protein units. Each protein consists 
of two functional domains – a TALE DNA binding domain (DBD) that carries out the 
task of sequence recognition and a FokI cleavage domain that carries out DNA cleavage. 
Because FokI cleavage domain naturally exists and functions as a dimer, two protein 
units oriented in a tail-to-tail configuration are necessary for TALEN function. Efforts to 
make monomeric TALEN either by choosing an alternate cleavage domain (7), which 
reduces the targeting range of TALE or by creating FokI tandem-dimer (8), which have 
markedly decreased activity. The main challenge for making monomeric TALEN work is 
the need to overcome non-specific cleavage activity and at the same time not limit the 
targeting possibility (7). Without the heterodimer structure, the cleavage activity is 




Figure 5.1  General TALEN structure. A single cut requires a pair of matched half-TALEN. 
 
The TALE DBD can be further divided into 3 subdomains, namely the N-terminus 
extension, the central repeat domain (CRD), and the C-terminus extension. Although the 
N- and C-terminus extensions do not appear to contribute to a TALE’s binding 
specificity, they are nonetheless essential for TALE binding. Crystallographic data 
suggests that the N-terminus is more rigid than the C-terminus (9, 10). Furthermore, it 
has been suggested the rigid N-terminus in facts recognizes a thymine base 5’ to the CRD 
recognition sequence (11). However, our prior work showed that this 5’-T specificity 
could be negated with a certain terminus truncation design (12). 
 
The CRD determines the binding specificity of the TALE, and it consists of multiple 
repeats of a 34 amino acids (aa) motif (13, 14). These repeats are nearly identical except 
at aa 13 and 14, which is known as the repeat variable diresidue (RVD), and it determines 
the DNA binding specificity of the given repeat. There’s a simple DNA binding code for 
the RVD – NI (Asp-Ile) for adenine, NG (Asp-Gly) for thymine, HD (His-Asp) for 
cytosine, NH (Asp-His) for guanine, and NN (Asp-Asp) for either guanine or adenine 
(15). Although the NH RVD exhibits better specificity for guanine, the NN RVD appears 









Being a popular genome editing platform, TALEN has been used to make genome 
modifications in a large range of hosts that includes yeast, worm, fish, mouse, cattle, and 
human, just to name a few (17). Coupled with either homologous recombination (HR) or 
non-homologous end joining (NHEJ) mechanism, TALENs have been successfully used 
to create gene knock-out (18), knock-in (19), replacement (20), and deletions (21). 
 
Currently, high-throughput synthesis of TALE DBDs are accomplished by connecting 
fragments taken from a library of pre-assembled parts, even though the exact mechanism 
and scheme used to connect the fragments varies (6, 18, 22-25). Understandably, the 
synthesis efficiency decreases as the number of fragments needed increases, regardless of 
the method used. As a result, most synthesis schemes seek to reduce the number of 
fragments in an assembly through one of two strategies – (1) by increasing the size of 
each fragment, or (2) by performing hierarchical assembly. Both of these strategies have 
their limitations. Increasing the size of each fragment will increase the size of the 
fragment library exponentially at a rate of 4n, where n is the number of TALE repeat in 
each fragment. On the other hand, performing hierarchical assembly will increase the 
number of synthesis steps and multiply the cost and time of assembly. 
 
With the exception of fairyTALE, a TALE synthesis method we previously developed, 
all other methods to date encountered assembly efficiency limitations at fewer than 10 
fragments (25). Given the challenge involved in the 1-step synthesis of just a single 
TALE, a 1-step synthesis of a TALEN pair in a single plasmid has never been achieved. 
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In this chapter, we built upon the ability of the fairyTALE synthesis platform to 
simultaneously ligate up to 15 fragments, and modified the system to allow for efficient 
1-step synthesis of TALEN pair in a single plasmid. Being able to synthesize TALENs in 
pairs led to the possibility of creating TALEN libraries, which could not be done with 
traditional TALEN pairs that are carried on two plasmids. Furthermore, even in cases 
where a library is not required, being able to make TALEN pairs in a single step 
immediately halves the cost of synthesis and the subsequent downstream processes. We 
call this new TALEN format: fairyTALEN. 
5.2	   Results	  
5.2.1	   Assembly	  scheme	  
The TALEN architecture used in this work is based upon the AvrXa10 TALE from 
Xanthomonas oryzae pv. oryzae as previously reported (25). In brief, it utilizes a +207 aa 
N-terminus extension and a +63 aa C-terminus extension, which negates the 5’-T 
requirement and allows greater flexibility in target sequence design (12). Attached at the 
C-terminus is an engineered FokI cleavage domain that showed greater cleavage 
efficiency in yeast as well as human cells (26). The CRD of both half-TALENs are 
constructed from a library of di-repeat substrates, i.e., each substrate contains two TALE 
repeats that recognize two consecutive DNA bases. For this work, we used a library of 
322 di-repeat substrates equally divided into 14 groups according to their position in the 
assembly. In addition to the 4^2 substrates to cover all possible DNA di-bases, we 
included the option to use either NH or NN to code for guanine. To separate the two half-
TALENs, we employed a poly-cistronic format that utilized a P2A self-cleaving 
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sequence(27). Both half-TALENs are coded as a single open reading frame, but the P2A 
peptide will cleave during translation, giving rise to two independent half-TALENs.  
 
Figure 5.2  FairyTALEN assembly scheme. 
 
In the fairyTALEN construction scheme, 2 sets of 7 di-repeats substrates, together with a 
linker substrate in between, are ligated onto a TALEN receiver vector in a single step via 
Golden Gate assembly. The N-terminus extension of the first half-TALEN and the C-
terminus extension of the second half-TALEN are carried by the vector, whereas the C-
terminus extension of the first half-TALEN and the N-terminus extension of the second 
half-TALEN are carried by the linker substrate. 4 TALEN receivers and 4 linker 
substrates are used in the assembly. This construction scheme ligates ~6kb worth of DNA 
in 15 fragments into a 5kb vector, and creates a TALEN pair that recognizes a 30bp 
sequence. 
5.2.2	   Assembly	  fidelity	  
With the demand of TALEN library creation in mind, we optimized the reaction 
condition to maximize the assembly fidelity. For library creation applications, picking 
individual clone for verification would be too expensive, and we would therefore need to 
ccdB C-Term FokI LR!N-Term 
C-Term FokI LR! N-Term P2A 
!"#$%&'!()%'*++%,-#.'
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achieve high assembly fidelity to allow us to skip clonal isolation without drastically 
affecting the quality of the library. We picked 28 colonies from a fairyTALEN assembly, 
and assessed them by restriction digest followed and gel electrophoreses. As shown in 
Figure 5.3, all 28 clones gave the correct digestion pattern. We then sequenced 4 of the 
clones and they all appeared to be correct. This (28/28) corresponds to a fidelity of at 








Figure 5.3 Gel electrophoresis of 28 
different fairyTALEN clones following 
HindIII, StuI digest. All clones showed 
the expected digestion pattern. The 
middle lane is NEB 1kb ladder. 
 
5.2.3	   P2A	  functionality	  
To ensure that P2A cleaves the protein effectively, we performed a western blot analysis 
from cell lysates of HEK293 that have been transfected with 4 different fairyTALEN 
plasmids. As shown in Figure 5.4, only TALEN monomer was detected and no dimer 







Figure 5.4 Western blot from the cell lysate of HEK293 expressing 
fairyTALEN. TALENs were detected using their FLAG tags and the 
loading control was alpha tubulin. Only the cleavage products were 









5.2.4	   FairyTALEN	  activity	  in	  HEK293	  
To gauge the DNA cleavage activity of fairyTALEN, we compared the cleavage 
efficiency of fairyTALEN against previously reported traditional TALEN. Two sites 
were chosen for this analysis, ABL1 and BRCA2. Cleavage efficiency was measured 
through Surveyor nuclease assay, which detects indel introduced via NHEJ after TALEN 
induced double stranded break. As shown in Figure 5.5a, the cleavage efficiency of the 
two fairyTALENs was comparable to that of traditional TALENs. The fairyTALENs 
used in this experiment used NH to recognize guanine, whereas the traditional TALENs 
used NN to recognize guanine. 
 
Figure 5.5 (a) Surveyor assay comparing the cleavage efficiency of fairyTALEN (FTN) and traditional 





















































































































































































triangle indicates the position of the expected band if indels occurred at the target site. The cleavage 
efficiency of FTN appeared comparable to that of traditional TALEN. (b) On the left of both rows are the 
mismatched TALEN negative controls. Top row: GFP inactivation assay comparing the cleavage efficiency 
of NN traditional TALEN and NH traditional TALEN. NH TALEN appeared inactive. Bottom row: GFP 
inactivation assay comparing the cleavage efficiency of NN traditional TALEN and NN FTN. 
FairyTALEN had roughly half the activity of traditional TALEN. 
 
To facilitate our development effort, we constructed a HEK293 reporter cell line that 
allows us to more quickly detect and measure DNA cleavage activity. A tdTomato-P2A-
EGFP cassette was stably integrated into HEK293, which allows us to achieve a Tomato-
GFP co-expression of close to 100%. By targeting the EGFP part of the cassette using 
TALEN and gating for the Tomato only population in flow cytometry, we can get a more 
quantitative measure of the cleavage efficiency. As shown in Figure 5.5b, the 
fairyTALEN had about half the activity of traditional TALEN. In addition, using NN to 
recognize guanine led to higher cleavage efficiency. However, more tests are needed to 
further elucidate the relationship because there are 13 guanines in the EGFP1 cut site, 
which is way above average. Taken together, we have shown that the fairyTALEN 
construct is functional in HEK293, albeit at a lower cleavage efficiency compared to a 
traditional TALEN. 
5.2.5	   FairyTALEN	  activity	  in	  hESC	  	  
Following the initial success in HEK293, we attempted to apply the fairyTALEN 
technology to perform enhancer activity screening in human stem cells. Enhancers are 
genetic regulatory elements that can affect transcription of genes over very long linear 
distance, as such, it has been very challenging for researchers to study their connectivity 
(28). Current experimental techniques mostly focus on identifying possible enhancers, 
however, experimental techniques that directly verifies these prediction are sorely 
missing(29). As a proof of concept we targeted a predicted Oct4 enhancer 40kb away 
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from the Oct4 gene, and monitored Oct4 expression through an EGFP reporter in the H1-
Oct4-EGFP human stem cell line (30). 
 
As shown in Figure 5.6a, targeting the enhancer region using TALEN produced an Oct4-
reduced stem cell population. Furthermore, the activity produced by the fairyTALEN was 
comparable to that of the traditional TALEN, even though the fairyTALEN in this case 
utilized NH to recognize guanine. There are only 7 guanine in the Ch6-1 cut site, which 
may explain why the use of NH did not significantly reduced cleavage efficiency.  
 
Figure 5.6 (a) Oct4 down-regulation assay for comparing enhancer disruption using traditional TALEN vs 
fairyTALEN. Negative control was H1-Oct4-EGFP cells transfected with bGal. The enhancer disruption 
capability of fairyTALEN was comparable to that of traditional TALEN. (b) Surveyor assay for comparing 
indel induction frequency between traditional TALEN vs fairyTALEN (FTN). In this case, fairyTALEN 
activity appear to be around ¼ that of traditional TALEN. 
 
To further evaluate fairyTALEN activity in hESC cells, we performed Surveyor assay on 
the ABL1 and BRCA2 sites with the same fairyTALEN and traditional TALEN 
constructs as we had used to in HEK293. However, in contrast to the result in HEK293, 
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the fairyTALEN activity appears markedly reduced compared to that of traditional 
TALEN.  
 
Promoter Activity in hESC. One way to increase TALEN cleavage efficiency is to simply 
increase the expression level of the TALEN. Because the CMV promoter we used to 
drive TALEN expression in HEK293 cells may in fact be repressed in hESC cells(31, 
32), we tested a panel of 6 constitutive promoters to see if we can find one that is the 
most active. In addition to CMV promoter, we included mPGK (murine PGK), EF1a, two 
truncations of Chef1a (CHO EF1a), and ACTB. Using the above promoters to drive a 
tdTomato reporter, we measured the relative activity of these promoters in H1-Oct4-
EGFP cells using flow cytometry. As shown in Figure 5.7, Chef1a1433 has by far the 
highest activity in H1 hESC cells. This is consistent with the result previously reported 
(33). By switching to a Chef1a receiver vector, we can potentially increase TALEN 








Figure 5.7 Relative strength of various promoters in 
H1-Oct4-EGFP cells in arbitrary fluorescence unit. 
 
5.3	   Discussion	  
We have constructed a functional single-plasmid fairyTALEN system that can be 
assembled efficiently and cost-effectively in a high-throughput compatible format. 









partially compensated through the use of a more efficient cleavage domain and possibly a 
stronger promoter. Previous research suggests that transient expression efficiency is 
adversely affected by increasing size of the expression plasmid, possibly due to difficulty 
related to nuclear pore transit (34, 35). If this is indeed the case, using lentiviral delivery 
should eliminate this bottleneck completely. In any case, even at half the efficiency of 
traditional TALEN, fairyTALEN should still serve well in genetic screening applications. 
 
Being able to assemble paired TALENs in a high-throughput manner will open up 
possibilities previously inaccessible with traditional TALEN technology. Future 
directions include genetic screening using a mixed library of fairyTALENs and multiple 
targeting using a collection of fairyTALENs. 
 
Besides TALEN, CRISPR is another popular technology used in genome editing 
applications (36). As oppose to using a specific protein to recognize DNA sequences, 
CRISPR utilizes RNA to perform the recognition through base pairing. Using a nucleic 
acid for targeting has many advantages, but most importantly, through the use of micro-
array DNA synthesis, a large nucleic acid library is readily accessible. As such, even 
though TALEN had a two-year head start over CRISPR, multiple targeting and genetic 
screening were both first achieved using CRISPR (37-39). However, due to its relatively 




In a genetic screening that targets structural genes, the off-target effect can be 
compensated by targeting multiple sites within the same gene, so that high confidence hit 
can be identified by looking for the enrichment of a set of sites instead of any single site. 
However, in the case where the functional DNA element is very small, e.g., a 
transcriptional enhancer, or a miRNA gene, there is simply not enough length to fit in 
multiple targeting sites. Furthermore, in the case of an enhancer, the target cut sites are 
transcription factor binding sites that are typically around 10bp. Given the limited range 
for target selection, CRISPR may not be able to find a site that is sufficiently unique in 
the genome. Developing screens for enhancer and miRNA is therefore a niche where the 
fairyTALEN technology will fit nicely. 
 
5.4	   Conclusions	  and	  outlook	  
To show that fairyTALEN can indeed serve as a screening tool for enhancer or miRNA, 
we will need a demonstration experiment. One possibility is to design a fairyTALEN 
library to target all predicted Oct4 enhancers, or all known miRNAs, both in the order of 
about a thousand, which is within the throughput capability of fairyTALEN. Using the 
H1-Oct4-EGFP cell line, we can screen for enhancer and miRNA targets that affects Oct4 
expression. 
 
To accomplish this, a barcoding compatible lentiviral delivery vector is needed. By using 
lentivirus delivery, we can control the infection multiplicity to make sure that we only 
have one fairyTALEN in each cell, which will make downstream target identification 
easier. By including a unique barcode for every fairyTALEN, we can easily track the 
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spread of the fairyTALEN population by next-generation sequencing, and it also allows 
for the easy identification of the possible target without having to sequence the entire 
fairyTALEN construct. 
5.5	   Materials	  and	  methods	  
5.5.1	   Substrate	  and	  receiver	  plasmid	  construction	  
Di-repeat substrates plasmids were constructed according to methods previously 
described (25). Linker substrate plasmids were modified from a group 6 di-repeat 
substrate, and they were to be used in place of group 6 substrate during fairyTALEN 
assembly. After BsaI excision of the original group 6 substrate fragment, 3 fragments – a 
PCR fragment containing the end of the first TALEN, a chemically synthesized gene 
fragment containing a P2A sequence and a HA epitope tag (Integrated DNA 
Technologies, Coralville, IA), and a second PCR fragment containing the start of the 
second TALEN – were inserted via Type IIs ligation. Receiver plasmids for use in 
mammalian cells were modified from the previously reported yeast pYW-LR-TN 
TALEN receivers by transferring the whole TALEN cassette to a modified mammalian 
expression vector that had had all BsaI sites removed. 
5.5.2	   Golden	  Gate	  assembly	  
All substrate plasmids and receiver plasmids were normalized to equal-concentration, 
diluted with water, and stored in 96-well storage plates. Using an epMotion liquid 
handling robot (Eppendorf, Hamburg, Germany), interfaced with a custom command 
script, the appropriate substrate and receiver plasmids were pipetted into a 96-well PCR 
plate. Due to the pipetting precision of the robotic system, 3 µL of each plasmid were 
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added for reproducible transfer, thus resulting in a final volume of >40 µL. The plasmid 
mixtures were first lyophilized before Golden Gate reaction. 30 ng of each di-repeat 
substrate plasmid, 60 ng of linker plasmid, and 60 ng of mammalian receiver plasmid, 
were used in a 20 µL Golden Gate reaction – 0.8 µL BsaI, 0.2 µL T4 ligase (New 
England Biolabs, Ipswich, MA) in 1× T4 ligase buffer. The reaction was carried out in a 
thermocycler using the following program: 37 ºC for 5 min, 37 ºC for 5 min, 16 ºC for 10 
min, repeat 2-3 for 30 cycles, 16 ºC for 20 min, 37 ºC for 30 min, 80 ºC for 6 min, 4 ºC 
hold. After the thermocycling, 0.5 µL of plasmid-safe nuclease (Epicentre, Madison, WI), 
and 1 µL of 25 mM ATP was added to the reaction, and incubated further at 37 ºC for 15 
min. 5 µL of the resultant reaction was transformed into either Z-competent (Zymo 
Research, Irvine, CA) or Stellar (Clontech, Mountain View, CA) E. coli. Competent cells 
with greater than 5×105/µg pUC19 transformation efficiency would suffice.  
5.5.3	   Tomato-­‐P2A-­‐EGFP	  reporter	  cell	  line	  
Using pSin-EF2-Oct4-Pur (Addgene 16579) as the starting vector, we excised the Oct4 
ORF with SpeI and BamHI. After that, a tdTomato PCR fragment from ptdTomato 
(Clontech, Mountain View, CA) and an EGFP PCR fragment with primer-introduced a 
P2A sequence are ligated to make pSin-EF2-Tomato-P2A-EGFP. The sequence verified 
plasmid was transfected into HEK293 cells using Fugene HD (Promega, Madison, WI) 
according to manufacturer’s recommendations. Two days after transfection, the cells 
were placed under 2µg/mL puromycin selection for a week until colonies start to form. 
24 colonies were isolated for flow cytometry analysis, and clones with tight co-
expression profiles were chosen for TALEN sensitivity evaluation. We transfected these 
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clones with a TALEN that targets EGFP and eventually selected the clone that appear the 
most sensitive to TALEN cleavage for all subsequent studies. 
5.5.4	   EGFP	  reporter	  inactivation	  assay	  
TALEN constructs under evaluation were transfected into the Tomato-P2A-EGFP 
reporter cell line described earlier using Fugene HD according to manufacturer’s 
recommendations. A day after transfection, the cells were passaged normally, and on the 
fourth day after transfection, flow cytometry assay was performed on a LSRII (BD 
Biosciences, San Jose, CA). We used a single 488 nm laser to excite both fluorescent 
proteins, a 530/30 channel to monitor EGFP and a 610/20 channel to monitor tdTomato. 
For analysis, we first gated for the Tomato positive cells and plotted them on a Tomato(y-
axis)-EGFP(x-axis) 2D scatter plot. Cells that were above the diagonal were not 
expressing EGFP and therefore an indication of EGFP disruption. For all assays, a 
mismatched pair of TALEN was used as a negative control. 
5.5.5	   Surveyor	  assay	  
Cells for the assay were harvested 2 days after transfection, and genomic DNA was 
extracted using Wizard genomic DNA purification kit (Promega, Madison, WI) 
according to manufacturer’s recommendations. The section of DNA containing the 
TALEN target site was PCR amplified, yielding a fragment size of between 500 to 
1000bp in total, centered evenly around the target site. The purified PCR product was re-
annealed and analyzed using Surveyor mutation detection kit (Transgenomic, Omaha, 
NE) according to manufacturer’s recommendations. The Surveyor cleavage product was 
resolved on a 2% agarose gel.  
% Indel = 100*(1-(1-fraction cleaved)1/2) 
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5.5.6	   Oct4	  down-­‐regulation	  assay	  
TALEN constructs under evaluation were transfected into H1-Oct4-EGFP stem cells 
(WiCell, Madison, WI) by nucleofection according to manufacturer’s recommendations. 
After optimization, we settled on the P4 Primary Cell 4D-Nucleofector Kit, and program 
CA-137 on the 4D-Nucleofector (Lonza, Cologne, Germany). Cells were passaged one 
day after nucleofection, and were harvested on the fourth day after nucleofection. After 
harvest, the cells were counted and stained using Alexa Fluor 647 conjugated SSEA4 
antibody (Life Technologies, Carlsbad, CA) at a concentration of 5 ×105 cells in 50µL 
PBS with 2% BSA and 2.5µL SSEA4 antibody. The cells were stained in the dark at 
room temperature for 30min, and washed 3 times in PBS before flow cytometry analysis. 
During analysis, the stem cell population was first selected by gating for the SSEA4 
positive cells. Within this population, we then look at the spread of EGFP expression, and 
gate for the EGFP-reduced population. 
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Appendix	  A:	  Supplementary	  figures	  for	  Chapter	  2	  
Supplementary Figure A.1 Result from the initial architecture optimization screening.  
V24P and P24V clearly outperformed the rest.  EGFP, EGFP+DHB, and GalP65 were 
used as negative controls.  EGFP+CoCl2 was used to emulate hypoxia and VZ8-P65 and 






















Supplementary Figure A.2 Range of induction levels from 12 different stable integrant 
clones.  Induction level ranged from 810 to 5100 pg/mL, averaged 2740 pg/mL.  Light 





















Supplementary Figure A.3 List of plasmids reported in this work 
 
Plasmid 
1 GAL-VP64 pCMV5 
2 GAL-p65 pCMV5 
3 p65(510-551)-VZ8-4S pCMV5 
4 p65(451-551)-VZ8-4S pCMV5 
5 p65(282-551)-VZ8-4S pCMV5 
6 p65(417-459)-VZ8-4S pCMV5 
7 p65(373-459)-VZ8-4S pCMV5 
8 p65(460-523)-VZ8-4S pCMV5 
9 V24P(451) pCMV5 
10 V24P-GS20 pCMV5 
11 V24P-GS40 pCMV5 
12 V24P-GS60 pCMV5 
13 V24P-GS80 pCMV5 
14 V24P-GS110 pCMV5 
15 P24V(451) pCMV5 
16 P24V-GS20 pCMV5 
17 P24V-GS40 pCMV5 
18 P24V-GS60 pCMV5 
19 V4 pCMV5 
20 Vg4 pCMV5 
21 4V pCMV5 
22 24V pCMV5 
23 V24 pCMV5 
24 4VP pCMV5 
25 P(451)V4 pCMV5 
26 P(284)V4 pCMV5 
27 VZ8-P65 pCMV5 
28 EGFP pCMV5 
29 V24P-GS60 pLNCX2 




Appendix	  B:	  Supplementary	  figures	  for	  Chapter	  3	  
Supplementary Figure B.1 Unique 4 bp overhang assignment in pathway assembly. 
 
By judiciously choosing the 4 bp overhang created by BsaI, pathways can be assembled 
in a user-specified order. The TP fragments and the receiver fragment (pRS416K2) are 








CATA CrtE GTAG CAAA CrtB CATC AACA CrtI TGAC CACA CrtY TCCG TACA CrtZ ATCC 
GTAG TP1 CAAA CATC TP2 AACA TGAC TP3 CACA TCCG TP4 TACA 
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Supplementary Figure B.2 Inducible zeaxanthin pathway stability assessment.  
 
The plasmids harboring the assembled zeaxanthin pathway were purified form E. coli and 
used to transform YZE-PA and YZE-55.  After two days incubation, the initial colonies 
were collected and re-plated onto an SC-URA plate with 0.1 µM estradiol. When 
colonies reappeared, the numbers of white and yellow colonies were counted. A yellow 
colony was subsequently picked for continuous cultivation in SC-URA media, diluted 
daily at 1/100. Aliquots of the continuous culture were plated on SC-URA with estradiol 

















y = 163.58x0.3095 


















mRNA Induction (Fold difference) 
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Supplementary Figure B.4 Primer sequences used in zeaxanthin pathway cloning. The 
black portion is gene-specific, and the blue portion is position-specific. The 4 bp 
overhangs are underlined, and they determine the order in which the genes are assembled. 
 
Primer Name Primer Sequences (5'-3') 
BsaI>-CrtE For CTTGAAGGTCTCCCATA ATGACGGTCTGCGCAAAAAAACAC 
CrtE-<BsaI Rev CAATAAGGTCTCGCTAC TTAACTGACGGCAGCGAGTTTTTTGTC 
BsaI>-CrtB For CTTGAAGGTCTCCCAAA ATGAATAATCCGTCGTTACTCAATCATGCG 
CrtB-<BsaI Rev CAATAAGGTCTCGGATG CTAGAGCGGGCGCTGCCAG 
BsaI>-CrtI For CTTGAAGGTCTCCAACA ATGAAACCAACTACGGTAATTGGTGCAGG 
CrtI-<BsaI Rev CAATAAGGTCTCGGTCA TCATATCAGATCCTCCAGCATCAAACCTG 
BsaI>-CrtY For CTTGAAGGTCTCCCACA ATGCAACCGCATTATGATCTGATTCTCG 
CrtY-<BsaI Rev CAATAAGGTCTCGCGGA TTAACGATGAGTCGTCATAATGGCTTGC 
BsaI>-CrtZ For CTTGAAGGTCTCCTACA ATGTTGTGGATTTGGAATGCCCTG 




Supplementary Figure B.5 Primer sequences used in quantitative RT-PCR. 
 
Primer Name Primer Sequence (5’-3’) 
ALG9 Forward CTACCATCAGAACCGCATTC 
ALG9 Reverse TCCATGATACAGGAGCAAGC 
crtB Forward TTGCGGCTTTTCAGGAAG 
crtB Reverse AATAGCGCAGCGTATCATCC 
crtE Forward AACTGCTGGACGATTTGACC 
crtE Reverse TCACTGGCAAGCTGAAGATG 
crtI Forward AAGCCGTGCATTTAGAGGAC 
crtI Reverse TCTGCAGTTTGTTGGACTGC 
crtY Forward TTGACTGAGAGCCAACATCG 
crtY Reverse TGTCGCTGTAAAACCTCAGC 
crtZ Forward GCCATTCCGCTATATTCCAC 




Supplementary Figure B.6  
SYN1 and SYN2 promoter sequences. 
 








SYN1C (2 x UAS) 
TATTGAAGTACGGAGTGTTAGGCTCCGGTACACGGAGTGTTAGGCTCCG-TATA GAL1 
 





























Appendix	  C:	  Supplementary	  figures	  for	  Chapter	  4	  
Supplementary Figure C.1 System expansion 
 
In a standard assembly, 13 fragments are assembled together in a single step and it 





In an extended assembly, 15 fragments are assembled together in a single step and it 
therefore requires 15 groups of substrate plasmids. To accommodate the extra groups, the 
group 5 position is expanded into (replaced by) group 5A,B,C. These extended assembly 
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Supplementary Figure C.2  Sequences of di- and mono-repeats 
 
To get to the sequence of any di-repeat, concatenate Front + RVD1 + RVD2 + Back, for 
mono-repeat, concatenate Front + RVDM + Back. For example, the Group 3, AT di-
repeat sequence is generated by concatenating all the sequences highlighted in pink. 
Annotation: Golden Gate assembly junction in blue, and unique primer annealing region 
in orange. 
 




































































































Supplementary Figure C.3 Specific yield estimation 
 
A standard product plasmid of known concentration was used to generate a 
transformation efficiency curve in the target E. coli strain. The plasmid standard was 
diluted in 1× T4 ligase buffer to mimic the buffer condition of ligation product. Below 
are two such curves for pYW-LR-TN-13 (final functional product) into Stellar Z-




Since the transformation efficiency is linear, we can estimate the amount of circular 
plasmid (apparent yield) present in the reaction by counting the number of colonies on a 
petri dish plate. 
 
Maximum theoretical yield is the ng mass of the product plasmid if all the backbones in 
the reaction were converted into product plasmid. For pLR assembly, the backbone is 
around 2.5 kb and the product is around 5 kb, and the maximum theoretical yield for a 
reaction with 25 ng of pLR is therefore 50ng. 
 
Specific yield is the apparent yield divided by the maximum theoretical yield, and can be 
estimated from colony number by 
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Supplementary Figure C.4 Sequencing traces 
 
Sample sequencing traces from a polyclonal plasmid preparation 
Read using forward primer annealing within the N-terminus region 
 
 
Read using internal forward primer annealing within the CRD 
 
 
Read using reverse primer annealing within the C-terminus region 
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Supplementary Figure C.5 Activity of 90 target sites 
 
Index is consistent with Supplementary Figure C.11. Activity is represented by 
normalized GFP fluorescence. Normalization was done against the activity of I-CreI, 
which had a GFP correction efficiency of between 0.1% and 0.3%. 
1 AAGTATCTAGATATTGCACACTGTATGTGA 18.0 46 TTTGGCTGTCTCGTAAAGAAACCATAGAAT 17.0 
2 TTCGGGTCATAATGCAAGCCTTTACCATTT 8.7 47 ATTAGTTAGCTGACGTATGGAACATCTCTG 15.3 
3 CTATCGACTTATCCGACCTCTTGTTGTTTG 15.9 48 TAAGGGGGAAATTTGCTGTTTACTAAAATA 14.1 
4 ATTTTTAAATTCATAATCATCTTAGACCGA 14.1 49 CCTTTACGAAAGATACTACCCCATAGCAAA 10.2 
5 TGATTAGTAGATGAATGACTCACTTTTTGG 10.9 50 TCTTTAGCTAGGGGAGAATATTCGCAATTG 12.3 
6 TAAGGACCTTTGCGCAGCCGTAAGGGGGTC 11.0 51 CACAACTGGCCAGGAACATATTCCAAGTTA 0.7 
7 AAATATGTTTATCCATTGGTGCGGTGATTG 13.2 52 GGAATCTGGTTCAGGTTTTCACATATATTT 10.8 
8 GTAATGAGTCAGCAAATCACTGTGTACGTT 2.1 53 AGGGGATGGTAAAACAAAGAAAACCAGCCA 14.1 
9 TTTACTCACAAATGGAATTCAAGGGGAACA 8.6 54 GAAAATGCAACGCTGCCCGTGCAGGGTTTT 8.1 
10 AACTAAGGTCCTGCCCGGAGTGAGCCAATA 18.1 55 CATAAAAAAAATACTACAGTAAAGAAAGGG 5.6 
11 TTCAAAAGAAATTTACTAAATAATACCAGT 0.2 56 ACAAGGAGTAGGAACCGTTCGGCAGCGAGT 7.6 
12 TGACGGCTATCATTTATTGTCAACATGCAT 5.2 57 CTGTACAGCTACATTTACTTATAAGACAAG 10.6 
13 ATGGCACTTTGATTTCCCTTTCCATCTCAC 17.9 58 CAAACCAGGTTTGTTTTGGCTTTTATTTGC 6.7 
14 AAAATGTCAATTGATATCCATCCATTATAT 12.3 59 GCATAACAGCTTAAACCGAATCCTCCTTAA 8.9 
15 ACCATGAGTCTTCTTCATCTTGTTTTATAT 8.8 60 AAGAGCTCAAAAGCAGGTAACTATATAACA 8.3 
16 ATAAGCTGGCGCAAATTGAAACATGTGAAA 6.0 61 AAAAGAAAAAATAATTATTAGAAACCAATT 9.5 
17 GGGAATACATTTCCGGGGTTGATCCTCGAG 6.8 62 ATTCGGATTCTGACAGAGCAAATTGAAACT 9.2 
18 GATATGATTTGTCTCCAGTAGTATAAGCAA 6.9 63 CTGAGCGGGATGAAAAAATCAGACAAATAT 4.8 
19 AATGCCTTTAACAACTTTTTTTTTCCCACA 4.1 64 TTCCCTCAACTAGGCCTACTTTTCATATAT 7.3 
20 ACTTCGGTCTCAGCACTTTAATTATTCTTC 5.8 65 GACAGTATGTTGAAACGTGCATCTTATAAT 10.0 
21 AAGCGGCCACAAATTACGCAGGAATCTATG 0.9 66 CCATTCCAAATTACCTATGTTTAAGTCTGT 10.7 
22 TTAAGAAGCGTTGGCTAGTGTCATATGCGG 0.0 67 AGTTGAGTTTCCAATAACATTATGCAGAAT 13.6 
23 TTGGGAAATAGTAAACAGCTTTGAGTAGTC 6.4 68 GAGCAATTAGTAGCGACGGGAGCAAGAACT 3.5 
24 CATCCTTCACGGTTTGGAATTTTTGAGTAA 2.6 69 ATTTAAGTAATTACAATTACAACCATTAAA 5.3 
25 ATCTTCAATTCTATTGTTTTTGAAAAAAAA 7.9 70 CATGCCTTACACTCTATCCGACGCTCATCA 19.0 
26 AAATGCTCAAAACTTGCAGCAACTATTCTT 15.5 71 AGACTAAGGCAAACATGTCAGACGGCACTC 9.3 
27 ATAATGCAGAACTTGCTTCCCTTAGTTTGC 15.0 72 ACCAACACAAGATGCTAAGATCAAATTTAT 7.5 
28 AAAAAAAAAAAGGATTATAAAAGGTCAGCG 1.0 73 TTTAGGATTTTTCCTTCTCCCAAAATACTC 10.3 
29 GAAAAGTGCTATCTATATAAGGAGAAGCCC 6.6 74 GGATATTATAGTGCTAAGTATATAGACTTC 11.9 
30 GCGCCAGATCTGTTTACTGTAAAATTAAGT 3.1 75 CCAAGTTATGAGTAATTACTTTGTTGGAAG 8.3 
31 AACTACTTCAACGATTGAAAGGATTATTCT 5.1 76 AATCTCTTTTTGAGCTTCAGGGGAGGAAAT 7.7 
32 TCGTTCCCACCTAATTTCGCAATTTATTGT 7.7 77 GGGCGCACGATTTATTTTATTTTAATTAAT 2.2 
33 GTTCCTAAAGCTTATTCTTATTCTACATTA 6.3 78 TGTTTATTCGGTTCTAGCCGCTGCTTTAGT 8.1 
34 GTTAGCCTATCTGTTTCTTCTTTCTTTCAC 8.4 79 CCTTACGGTCACTTTACTAACAATACCACG 19.1 
35 CTATGCAACATATATAAGTGCTTAAATTTG 7.2 80 AAAAAGGATAGAGGATGGCGAAAAGCAAAT 5.7 
36 AAAAGGACTGAACATGACAAAAAATAGAGA 9.9 81 AAGAAAATAAGGCAAAACATATAGCAATAT 4.5 
37 AAAAAATAAAAAAAAAAAAGATTAAAGGCA 1.5 82 TAAGTTGATCACCTCTCATTTGGTGGACAC 17.4 
38 TACCCTTCCCCTGTTATGGATTGCTAGTCT 8.0 83 AAAAACTATGGGGTGGGAGATTCACTGGTG 9.1 
39 GTTCAGTAATCTTTCCTTCTTCTAGTGTAA 18.0 84 GCAGAGGATCTCGAATCCTTGCAAGACTGA 0.7 
40 AAGCACAGAACTCTGAGATAAGACTACCTT 3.9 85 ACTTACTGTGTTACATTACAGAAAGAACAG 7.1 
41 TTCTAGATCCAAATATCAGGGGTAACTCTT 11.4 86 TGTTTTGTTCTTTAAAACTAAATAAAAAAA 6.9 
42 GAGTAATCTCGCGGGATGTAATGATTTAAG 15.0 87 GAGGGAGCAGAGGATAAGGAAATTCTTAAA 3.8 
43 CCTTGACTTCTACCACGAGAAAAAAATTAA 10.9 88 ATCTAACGTAAAAAAAAGAAAAATCCGAAA 0.2 
44 GCACCATTCTACTACAGGGCTCGGATCCAC 12.2 89 TTTTTAGTTATTTCGTATCGTACTAACAAC 9.2 
45 CTGGATGGAAGTCAATTATGCCTTGATTAT 3.5 90 TAATGCAGGTACAATTCCCCTCGGAGAGTT 10.9 
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Supplementary Figure C.6 Breakdown of cost estimate 
 
A summary of all reagents and consumables used in the production of a TALE expression 
plasmid.  
 
Item Cost # of Rxn Cost per Rxn 
T4 DNA Ligase $256 500 $0.51 
BsaI-HF $252 500 $0.50 
Plasmid-Safe Nuclease $214 2000 $0.11 
Z-Competent Cell $108 600 $0.18 
Plasmid Miniprep $367 250 $1.47 





Consumables include pipet tips, micro-tubes, 96-well plates, and other plastic disposable 
items. 
 
In a library synthesis approach, i.e. a mixture of TALE plasmids, the cost per TALE can 





Supplementary Figure C.7 Substrate plasmid construction 
 
Using a separate Golden Gate reaction scheme, RVD1, RVD2, RVDM can be inserted 
into pre-made pFB plasmids containing the front and back bridging sequences. The 
assembled di- and mono-repeat fragments can be excised by BsaI during the subsequent 





The pFB plasmids were prepared clonally, in which one clone was initially picked for 
every substrate plasmid. Restriction digestion confirmation indicates that the success rate 
was ~97% (70/72). In the figure below, the number below each lane is the expected size 
of the lower band, and any detectable error is highlighted in red. For sequencing 
confirmation, we first assembled them into a CRD, and then sequence the assembled 
CRD. Sequencing identified an additional 1% error, such as frame-shift, that is not 















Continuation of Supplementary Figure C.7	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Supplementary Figure C.8 Receiver plasmid construction 
 
Plasmid maps for pLR and pYW-LR-TN. The last repeat is first inserted by In-Fusion 
through the XcmI site. Multiple unique sites have been included in pYW-LR-TN so that 
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Supplementary Figure C.9 Golden Gate reaction optimization 
 
Golden Gate Junctions. The Golden Gate junctions were chosen based a three criteria. (1) 
They have GC content of at least 50%, (2) they are non-palindromic, and (3) they are not 
the same as the reverse-complement of any other junctions within the set – e.g., ATCC 
cannot co-exist in the same set as GGAT, or else unintended ligation product can form, 
leading to drastically reduced efficiency. In earlier junction sets we tested, we found that 
100% GC content junctions reduced the overall efficiency. This led us to suspect that 
matched junction Tm could be a contributing factor to high efficiency. 
 
Reaction Condition. Reaction condition optimization was carried out in 20µL reaction 
volume using a pLR receiver with LacZα screening marker instead of ccdB counter-
selection marker to help with troubleshooting. Optimization parameters include 
BsaI:ligase ratio, receiver amount, insert:vector ratio, the number of thermo-cycle, and 
the condition for plasmid-safe nuclease treatment. 
 
First, we determined the best vector amount at a constant (1:1) insert to vector ratio. This 
was done by counting the number of blue and white colonies after transformation and 
plating. 
  
We found that higher receiver amount will lead to higher background. While 25ng of 
receiver gave the lowest background, 50ng of receiver gave the highest number of white 




We found that having 1:1 insert:vector ratio gave the highest number of white colony in 
both cases. Next, we checked the thermo-cycling requirement using a fixed vector 




































Continuation of Supplementary Figure C.9	  
 
  
We found that thermo-cycling was crucial for the reaction, and higher cycle number was 
generally better. However, higher cycle number also meant longer reaction time. We 
recommend a minimum of 15 cycles for improved efficiency. 
  
The use of plasmid-safe nuclease after the thermo-cycle improved the efficiency of 
assembly by digesting any non-circular DNA remaining in the reaction. Due to the high 
homology between TALE repeats, non-circular DNA could recombine after 
transformation to form wrongly assembled plasmids. We previously noted a reduced 
specific yield when too high a concentration of plasmid-safe nuclease was used. We 
recommend a maximum of 0.5µL (2.5U) enzyme per 20µL reaction. 
 
Enzyme Ratio. In the course of this process development, we have noted significant 
difference in BsaI enzyme performance between different lots. The differences may not 
matter much in normal digestion, but can drastically affect a Golden Gate reaction.  
 
Most part of this work have been done using BsaI-HF and T4 DNA ligase (both from 
New England Biolabs, Ipswich, MA) at 1:1 BsaI to ligase ratio. However, if user 
experiences trouble with these reagents, we have found success using BsaI (non-HF) and 
T4 DNA ligase at 4:1 ratio, using exactly the same reaction condition as that described in 
the manuscript. 
 
As a third alternative, FastDigest Eco31I from Thermo Scientific can be paired with T4 
DNA ligase from Thermo Scientific at 4:1 ratio using a 37ºC/22ºC thermo-cycle instead 
of a 37º/16ºC thermo-cycle.  
 
We recommend users to test each lot of enzymes in a pilot scale assembly before moving 













Supplementary Figure C.10 Assembly efficiency assessment 
 
After Golden Gate assembly and Z-transformation, the transformants were each split into 
two parts. 1/3 of it were plated for colony picking and monoclonal DNA prep. 2/3 of it 
were directly inoculated into liquid culture for polyclonal DNA prep. The plasmids 




In our characterization, we have also analyzed (at least) 42 clonal plasmids from (at least) 
14 different assemblies (3 x 14) instead of 42 clonal plasmids from 1 single assembly. 
This is because the assembly efficiency could vary depending on the assembly context, 
and may therefore differ significantly. If the assembly efficiency is similar in all 
assembly context, then the observed efficiency of 42 clonal plasmids from 14 assemblies 
will be the same as that from 1 assembly. When an error is detected in one assembly, it 
could either reflect the true average efficiency, i.e. a random error, or it could indicate a 
particular assembly with increased error rate, i.e. a systematic error. To eliminate the 
possibility of the later, we always pick more colonies from assemblies that have shown at 
least one error for further analysis. 
	  













Supplementary Figure C.11 Sequences of 90 target sites 
Yeast ORF name followed by the site’s position relative to the transcriptional start site. 
The 3 bp preceding the actual binding site is included. The Xa10 half-site used in the 
yeast reporter system was TATATAAGCACGTATCT. 
 
1 YPR045C-150 AAGTATCTAGATATTGCACACTGTATGTGA 46 YPR045C-30 TTTGGCTGTCTCGTAAAGAAACCATAGAAT 
2 YOR229W-150 TTCGGGTCATAATGCAAGCCTTTACCATTT 47 YOR229W-30 ATTAGTTAGCTGACGTATGGAACATCTCTG 
3 YNR001C-150 CTATCGACTTATCCGACCTCTTGTTGTTTG 48 YNR001C-30 TAAGGGGGAAATTTGCTGTTTACTAAAATA 
4 YLR058C-150 ATTTTTAAATTCATAATCATCTTAGACCGA 49 YLR058C-30 CCTTTACGAAAGATACTACCCCATAGCAAA 
5 YHR018C-150 TGATTAGTAGATGAATGACTCACTTTTTGG 50 YHR018C-30 TCTTTAGCTAGGGGAGAATATTCGCAATTG 
6 YHL021C-150 TAAGGACCTTTGCGCAGCCGTAAGGGGGTC 51 YHL021C-30 CACAACTGGCCAGGAACATATTCCAAGTTA 
7 YGR019W-150 AAATATGTTTATCCATTGGTGCGGTGATTG 52 YGR019W-30 GGAATCTGGTTCAGGTTTTCACATATATTT 
8 YER089C-150 GTAATGAGTCAGCAAATCACTGTGTACGTT 53 YER089C-30 AGGGGATGGTAAAACAAAGAAAACCAGCCA 
9 YER081W-150 TTTACTCACAAATGGAATTCAAGGGGAACA 54 YER081W-30 GAAAATGCAACGCTGCCCGTGCAGGGTTTT 
10 YDR148C-150 AACTAAGGTCCTGCCCGGAGTGAGCCAATA 55 YBR092C-30 CATAAAAAAAATACTACAGTAAAGAAAGGG 
11 YBR092C-150 TTCAAAAGAAATTTACTAAATAATACCAGT 56 YPR045C+1 ACAAGGAGTAGGAACCGTTCGGCAGCGAGT 
12 YPR045C-120 TGACGGCTATCATTTATTGTCAACATGCAT 57 YOR229W+1 CTGTACAGCTACATTTACTTATAAGACAAG 
13 YOR229W-120 ATGGCACTTTGATTTCCCTTTCCATCTCAC 58 YNR001C+1 CAAACCAGGTTTGTTTTGGCTTTTATTTGC 
14 YNR001C-120 AAAATGTCAATTGATATCCATCCATTATAT 59 YLR058C+1 GCATAACAGCTTAAACCGAATCCTCCTTAA 
15 YLR058C-120 ACCATGAGTCTTCTTCATCTTGTTTTATAT 60 YHR018C+1 AAGAGCTCAAAAGCAGGTAACTATATAACA 
16 YHR018C-120 ATAAGCTGGCGCAAATTGAAACATGTGAAA 61 YHL021C+1 AAAAGAAAAAATAATTATTAGAAACCAATT 
17 YHL021C-120 GGGAATACATTTCCGGGGTTGATCCTCGAG 62 YER089C+1 ATTCGGATTCTGACAGAGCAAATTGAAACT 
18 YGR019W-120 GATATGATTTGTCTCCAGTAGTATAAGCAA 63 YER081W+1 CTGAGCGGGATGAAAAAATCAGACAAATAT 
19 YER089C-120 AATGCCTTTAACAACTTTTTTTTTCCCACA 64 YDR148C+1 TTCCCTCAACTAGGCCTACTTTTCATATAT 
20 YER081W-120 ACTTCGGTCTCAGCACTTTAATTATTCTTC 65 YDL189W+1 GACAGTATGTTGAAACGTGCATCTTATAAT 
21 YDR148C-120 AAGCGGCCACAAATTACGCAGGAATCTATG 66 YBR092C+1 CCATTCCAAATTACCTATGTTTAAGTCTGT 
22 YDL189W-120 TTAAGAAGCGTTGGCTAGTGTCATATGCGG 67 YPR045C+30 AGTTGAGTTTCCAATAACATTATGCAGAAT 
23 YBR092C-120 TTGGGAAATAGTAAACAGCTTTGAGTAGTC 68 YOR229W+30 GAGCAATTAGTAGCGACGGGAGCAAGAACT 
24 YPR045C-90 CATCCTTCACGGTTTGGAATTTTTGAGTAA 69 YNR001C+30 ATTTAAGTAATTACAATTACAACCATTAAA 
25 YOR229W-90 ATCTTCAATTCTATTGTTTTTGAAAAAAAA 70 YLR058C+30 CATGCCTTACACTCTATCCGACGCTCATCA 
26 YNR001C-90 AAATGCTCAAAACTTGCAGCAACTATTCTT 71 YHR018C+30 AGACTAAGGCAAACATGTCAGACGGCACTC 
27 YLR058C-90 ATAATGCAGAACTTGCTTCCCTTAGTTTGC 72 YHL021C+30 ACCAACACAAGATGCTAAGATCAAATTTAT 
28 YHR018C-90 AAAAAAAAAAAGGATTATAAAAGGTCAGCG 73 YGR019W+30 TTTAGGATTTTTCCTTCTCCCAAAATACTC 
29 YHL021C-90 GAAAAGTGCTATCTATATAAGGAGAAGCCC 74 YER089C+30 GGATATTATAGTGCTAAGTATATAGACTTC 
30 YGR019W-90 GCGCCAGATCTGTTTACTGTAAAATTAAGT 75 YER081W+30 CCAAGTTATGAGTAATTACTTTGTTGGAAG 
31 YER089C-90 AACTACTTCAACGATTGAAAGGATTATTCT 76 YDR148C+30 AATCTCTTTTTGAGCTTCAGGGGAGGAAAT 
32 YER081W-90 TCGTTCCCACCTAATTTCGCAATTTATTGT 77 YDL189W+30 GGGCGCACGATTTATTTTATTTTAATTAAT 
33 YDR148C-90 GTTCCTAAAGCTTATTCTTATTCTACATTA 78 YBR092C+30 TGTTTATTCGGTTCTAGCCGCTGCTTTAGT 
34 YDL189W-90 GTTAGCCTATCTGTTTCTTCTTTCTTTCAC 79 YPR045C+60 CCTTACGGTCACTTTACTAACAATACCACG 
35 YBR092C-90 CTATGCAACATATATAAGTGCTTAAATTTG 80 YOR229W+60 AAAAAGGATAGAGGATGGCGAAAAGCAAAT 
36 YPR045C-60 AAAAGGACTGAACATGACAAAAAATAGAGA 81 YNR001C+60 AAGAAAATAAGGCAAAACATATAGCAATAT 
37 YOR229W-60 AAAAAATAAAAAAAAAAAAGATTAAAGGCA 82 YLR058C+60 TAAGTTGATCACCTCTCATTTGGTGGACAC 
38 YNR001C-60 TACCCTTCCCCTGTTATGGATTGCTAGTCT 83 YHR018C+60 AAAAACTATGGGGTGGGAGATTCACTGGTG 
39 YLR058C-60 GTTCAGTAATCTTTCCTTCTTCTAGTGTAA 84 YHL021C+60 GCAGAGGATCTCGAATCCTTGCAAGACTGA 
40 YHR018C-60 AAGCACAGAACTCTGAGATAAGACTACCTT 85 YGR019W+60 ACTTACTGTGTTACATTACAGAAAGAACAG 
41 YHL021C-60 TTCTAGATCCAAATATCAGGGGTAACTCTT 86 YER089C+60 TGTTTTGTTCTTTAAAACTAAATAAAAAAA 
42 YGR019W-60 GAGTAATCTCGCGGGATGTAATGATTTAAG 87 YER081W+60 GAGGGAGCAGAGGATAAGGAAATTCTTAAA 
43 YER081W-60 CCTTGACTTCTACCACGAGAAAAAAATTAA 88 YDR148C+60 ATCTAACGTAAAAAAAAGAAAAATCCGAAA 
44 YDR148C-60 GCACCATTCTACTACAGGGCTCGGATCCAC 89 YDL189W+60 TTTTTAGTTATTTCGTATCGTACTAACAAC 
45 YBR092C-60 CTGGATGGAAGTCAATTATGCCTTGATTAT 90 YBR092C+60 TAATGCAGGTACAATTCCCCTCGGAGAGTT 
 
 
